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Abstract: 
In drug product packaging, migration of components from the container closure system into 
final formulation can compromise the therapeutic effect of the active pharmaceutical 
ingredient (API) or pose a health risk to the consumer. In response to this, regulatory 
expectations have elevated so that pharmaceutical companies show due diligence in the 
detection, quantitation, identification and monitoring of leachables through the shelf life of 
product. This work describes methods for the screening, quantification and identification of 
potential leachables in ophthalmic solutions. Particular focus was given to developing 
analytical separations using quality by design (QbD) principles. 
 An ultra performance liquid chromatography (UPLC) method was developed for the 
analysis of 8 potential leachables in ophthalmic solutions. The method was optimized in the 
centre of a design space using fractional factorial design of experiments (DOE) ensuring 
baseline resolution while minimizing analytical run time. Repeatability validation studies were 
assessed using process capability (CpK) techniques. The test method was geometrically 
transformed to allow simultaneous analysis on high performance liquid chromatography 
(HPLC) test systems. Mass spectra were generated for the leachables using an electrospray 
ionization (ESI) ion trap mass spectrometer. 
 An extraction and leachable study was executed on an ophthalmic solution under 
long term stability conditions in Chapter 3. The screening profile and concentration of 
leachables in the final drug product was monitored with consideration for time, temperature 
and humidity variables. The structural identity of any detected leachables were unknown and 
were tracked using their retention time relative to the reference standard. A single leachable 
was detected and the unidentified leachable was qualified through extraction of the 
packaging components from the container closure system (Stage I) and comparison to LC 
profile of the long term stability analysis (Stage II). The identification was confirmed using the 
LC-MS analytical method developed in Chapter 2. A single leachable, diethyl phthalate, 
identified using MS, was found to be present due to the adhesive used on the tamper 
19 
 
evident seal packaging component. It was quantitated against a qualified reference standard 
at a maximum level of 8 ppm. The level of 8 ppm is below the allowed 10 ppm threshold 
level as stipulated by the FDA 
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1. Introduction 
The global pharmaceutical industry is a thriving business and the global pharmaceutical 
market value is expected to expand to over $975 billion by 2013.1 Pharmaceutical 
companies develop new product lines in response to medical and aesthetic indications of a 
global population. Success for any pharmaceutical company is primarily dependent on the 
products efficacy towards a particular ailment. The symbiotic relationship that exists between 
company and customer is the driving force for new product development. Vast amounts of 
money are budgeted by corporate Chief Executive Officers (CEOs) towards research and 
development of new drug substances in the hope that the next “wonder drug” is unearthed.2 
The time and money resources required to bring a new drug product from R&D to the high 
street pharmacy is immense.3 The drug substances are formulated with various raw 
materials such as preservatives, antioxidants and excipients and packaged for delivery to 
market. The formulation matrix is designed to optimize the efficacy of the drug substance 
and increase shelf-life of the drug product. Capital investment into early stage drug 
development and clinical trial investigations could be rendered worthless through the use of 
unsuitable packaging. Migration of components from the container closure system into final 
formulation can compromise the therapeutic effect of the active pharmaceutical ingredient 
(API) or pose a health risk to the consumer. Not only is the direct toxicity of the transferred 
material a concern but the interaction with it and the API and other product components may 
lead to harmful degradation products. The terms used for these migrating entities are 
Extractables and Leachables.4 
An extractable may be defined as a chemical species which migrates under stressed 
conditions from any component involved in the manufacturing and packaging process. The 
rate of migration may be dependent upon solvent strength, exposure time and elevated 
temperatures. The term extractables encompasses all theoretical impurities which may elute 
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into the final product due to the use of stressed conditions. Leachables are a subset of 
extractables, as a leachable is a chemical species which can migrate into the product under 
normal conditions. The normal conditions are the recommended storage requirements of the 
final product and the extraction solvent is the actual final product. Degradants are impurities 
which are directly related to the breakdown products of the API. They may be a 
consequence of the natural stability of the API or as a result of an interaction between the 
API and a leachable. There are a number of sources from which a leachable may enter final 
product including equipment used in the manufacturing process which is in direct contact 
with the formulation and the final packaging. The primary source for leachables is the 
packaging components of the container closure system. The packaging components can be 
broken down into three subcategories, all of which have the potential to result in leachables.5 
(a) Primary Packaging Components 
The packaging items which are in direct contact with the final product and holds the unit 
formulation. These items pose the greatest risk for potential leachables. Typical examples of 
primary packing components are low or high density polyethylene (LDPE/HDPE) containers. 
Phthalate plasticizers used in the manufacture of primary containers are a typical example of 
migrating components.   
(b) Secondary Packaging Components 
The packaging components which are in direct contact with the primary packaging 
component or holds a number of primary packaging units together. Typical examples are 
labels, inks, adhesives or a LDPE overwrap to hold single units together. Secondary 
components are less likely to result in leachables at a significant level. Benzophenone 
initiator used in the UV ink curing process is an example of a component which can migrate 
into final product from the secondary packaging.6 
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(c) Tertiary Packaging Components 
The packaging components used for the distribution of product. Typical examples are 
palletized product for storage and shipping. Fungicide which has been used for treatment of 
wood pallets can potentially migrate into the final product from the tertiary packaging.7 
The subject area of extractables and leachables has become a focus point for the 
regulatory agencies recently which subsequently merits due diligence by the product 
manufacturer i.e. the care that a reasonable person exercises to avoid harm to other 
persons.8, 9, 10 It was in 1999 that The United States Food and Drug Administration (FDA) 
issued a guidance document in relation to packaging requirements for new drug products.11 
The guidance within this document stipulates that the compatibility of the drug product with 
the primary container closure system be established. Exact procedures for establishing the 
compatibility are not provided for within the guidance document and this has meant that the 
selection process for container closure systems between pharmaceutical companies may 
vary. The Orally Inhaled and Nasal Drug Products (OINDP) sector of the pharmaceutical 
industry have taken the initiative in relation to extractables and leachables.12 The 
International Pharmaceutical Aerosol Consortium for Regulation and Science (IPAC-RS) and 
the Product Quality Research Institute (PQRI) Leachables and Extractables Working Group 
have studied leachables and extractables in OINDP and submitted proposals to the FDA 
regarding safety and analytical thresholds.12, 13 
The detection, quantification and characterization of leachables in drug products 
provides a challenge as the leachables are present at low part per million (ppm) 
concentrations and there are interfering matrix effects of raw materials in the final product. 
This challenge is often overcome by combining a number of analytical techniques and 
strategies. Analytical strategies will differ depending on the product matrix, whether at early 
stage product development or marketed product. In the case of organic extractables and 
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leachables, regulatory agencies have recommended the use of Gas Chromatography (GC) 
and Liquid Chromatography (LC) for the separation of leachable components and either 
Flame Ionization Detection (FID), Ultra-violet (UV) or Mass Spectrometry (MS) for their 
detection and quantitation.14 The volatility (or other physical characteristics) of the chemical 
species will often determine the best route of analysis. Advances in analytical technology 
has allowed for improved separations with a high level of certainty for structure elucidation. 
Early day LC/UV systems permitted the basic screening of unknown compounds within the 
pharmaceutical product. The unknown peaks could be somewhat categorised as either a 
leachable or degradation substance by the use of a control sample which had no contact 
with the container closure system. Use of control samples, however, does not conclusively 
account for products which may be produced as a result of an interaction between the API 
and a leachable. An API- leachable degradant may elute at the same retention time as a API 
degradant and consequently be misidentified during analysis. The development of 
photodiode array (PDA) detectors meant that UV spectra of the unknown compound could 
be generated affording structural information about the class of compound. PDA analysis 
can detect compounds which have similar UV spectra and exhibit chromophores at the same 
wavelength, but will not give the required structural information to aid in the identification of a 
compound. MS was deemed a scientific breakthrough for the identification of unknown 
analytes across a broad spectrum of industries. MS detects molecular weight and elemental 
composition of substances and combined with known fragmentation patterns allows for 
structure elucidation with a high level of confidence. The ability for an analytical scientist to 
identify an unknown component is not only limited to the available MS instrumentation but 
also the instrument method parameters which are validated to run on the particular 
instrument. Consequently, there is greater focus on producing more robust methods at the 
initial development stage.15 The quest for the development of robust HPLC methods is 
documented by Molnar.16 
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The benefits of incorporating improved statistical analysis and introducing a quality-by-
design (QbD) approach to analytical method development and validation are being 
recognised by the authorities. Historically, QbD principles were implemented in early stage 
drug development to improve robustness and increase output for manufacturing processes. 
These principles, such as defining the critical quality attributes (CQAs) are transferable to 
the development, validation and control of analytical methods.16, 17, 18 
1.1 Extractables and Leachables 
The FDAs Centre for Drug Evaluation and Research (CDER) provides a definition for 
extractables and leachables and distinguishes between the two.11  
“The term extractable is specific to a container/closure material. A compound is said to 
be an extractable if it is identified in solvents that were exposed to the virgin container 
material under standard conditions, as specified in the USP. A compound is said to be a 
leachable if it is identified in the drug product following storage of that product, but was not 
identifiable in the product initially (assuming the compound is not a degradation product). 
Therefore, an extractable is a theoretical impurity of a drug product that utilizes a 
container/closure known to be associated with that extractable compound, while a leachable 
is a known impurity of a given product.”  
The FDA‟s concern for drug product stability and purity has led to an increased focus on 
pharmaceutical manufacturing processes and final container closure systems. In particular, 
the potential for chemical species from the processing equipment or packaging components 
to migrate into the product and have a negative impact on drug product must be assessed. 
Plastic components, sterilization by-products, adhesives, fungicides, inks and accelerants 
are among the possible sources for leachables. Figure 1.1 illustrates a number of sources 
for potential leachables migration into final drug product. 
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Figure 1.1: Cause and Effect Diagram for Potential Leachables in Final Drug Product  
 
Extractables and leachables are not just bound to the final packaging configuration 
but also to the actual manufacture of product. Single-use process equipment including 
bioreactors, buffer preparation, storage of bulk formulations and filling of single unit-dose 
containers must all address the issue of potential extractables and leachables.19 The FDAs 
commitment to this is highlighted in recent 483 observations (Warning Letters).20 In one 
case, in a drug product purification process, the company had only performed extractable 
and leachable testing on the  0.22 µm sterilizing filter and neglected to perform the same 
analysis on the other equipment and materials used in the purification. The regulatory need 
to perform adequate extractable and leachable testing on all components is well justified. At 
the turn of the 21st Century, an increase was observed in the number of patients suffering 
from antibody-positive pure red cell aplasia (PRCA), all of whom were using the Johnson & 
Johnson product Eprex®.21, 22 The formulation matrix was changed to include Polysorbate-80 
as a drug product stabilizer in 1998. This change aided the leaching of organic components 
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such as dialkylphenol disulfide from uncoated rubber stoppers used in the Eprex® syringe 
and subsequently was proven to be responsible for the increased incidence of PRCA. 
Pfizer®, Depomed® and Johnson & Johnson McNeil® have all had product recalls after 
numerous customer complaints were made about unusual odours from their products 
Lipitor®, Glumetza® and Tylenol®, respectively. The source of the odour in all cases was 
attributed to 2,4,6-tribromoanisole (TBA) which is a biomethylation product of 2,4,6-
tribromophenol fungicide used on wooden pallets for the shipping and storage of samples. 
The biomethylation reaction occurs where 2,4,6-tribromophenol is converted to 2,4,6-
tribromoanisole via metabolic transformation by xerophilic fungi. In all cases the lumbar was 
sourced from South America where moisture content > 20% and temperature range 25 – 
35°C. The TBA migrated through the tertiary, secondary and primary packaging components 
into the final product.20  
In response to the need for regulatory direction, CDER produced a guidance 
document for industry on container closure systems for packaging human drugs and 
biologics.11 This document classifies the safety concerns associated with packaging 
components for aerosols, injections, ophthalmic solutions and transdermal ointments and is 
summarized in Table 1.1.  
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Table 1.1: FDA Packaging Concerns for Various Classes of Drug Products9 
Degree of Concern 
Associated with 
the route of 
Administration 
Likelihood of Packaging Component-Dosage Form Interaction 
High Medium Low 
Highest Inhalation Aerosols 
and Solutions; 
Injections and 
Injectable 
Suspensionsa 
Sterile Powders and 
Powders for 
Injection; Inhalation 
Powders 
 
High Ophthalmic Solutions 
and Suspensions; 
Transdermal 
Ointments and 
Patches; Nasal 
Aerosols and Sprays  
  
Low Topical Solutions 
and Suspensions; 
Topical and Lingual 
Aerosols; Oral 
Solutions and 
Suspensions 
Topic Powders; Oral 
Powders  
Oral Tablets and 
Oral (Hard and Soft 
Gelatin) Capsules 
a  For the purpose of this table, the term suspension is used to mean a mixture of two 
immiscible phases (e.g. solid in liquid or liquid in liquid). As such it encompasses a wide 
variety of dosage forms such as creams, ointments, gels, and emulsions, as well as 
suspensions in the pharmaceutical sense. 
Inhalation aerosol represent the highest degree of concern associated with the route 
of administration and the highest likelihood of packaging component-dosage form 
interaction. Conversely, oral tablet and capsules provide the lowest degree of concern 
associated with the route of administration and the lowest likelihood of packaging 
component-dosage form interaction. The proposed packaging should be appropriate for the 
intended use of the product. Specifically, “Every proposed packaging system should be 
shown to be suitable for its intended use: it should adequately protect the dosage form; it 
should be compatible with the dosage form and the route of administration”.13 The FDA 
CDER group also stipulate that 
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“Packaging components should be constructed of materials that will not leach 
harmful or undesirable amounts of substances to which a patient will be exposed when 
being treated with the drug product”. 13  
Although the probability of migration is greatest with the material in direct contact with 
the final product (e.g. bottle resin), other components (e.g. inks and adhesives) should also 
be assessed for their potential to migrate through the barriers into the final dosage form. Use 
of plastic materials for pharmaceutical containers has increased with polyethylene, 
polypropylene, polyvinylchloride, polyester and laminated materials containing multiple 
polymers constituting various make-ups. Leachables can include but not limited to residual 
monomer building blocks or additives to make the plastic strong or malleable, colourants, UV 
stabilizers, initiators or catalysts. Low density plastic components pose less of a migration 
barrier than high density components. As a result, in low density plastics, the leachable 
concentration in a drug product may increase due to increased migration of chemical 
species from the packaging component and also a tandem loss of water through the semi-
permeable membrane. 
Not only does the potential for packaging component migration have to be addressed 
but the associated toxicology of that migration must be determined.23, 24, 25, 26 Firstly, 
extraction experiments need to be carried out on the packaging components and then a 
toxilogical study must be performed on the extracted components to assess patient impact. 
Typically, the packaging component is placed in a suitable solvent at elevated temperatures 
(to increase rate of extraction) and the solvent is analysed for extractables. The preferred 
solvent is the formulation matrix (if possible) as this would reflect what is likely to occur in 
final marketed product. Although these extraction studies are performed in the product 
development phase, the only true way to assess potential extractables and leachables is 
over the shelf life of the product with appropriate supporting toxilogical data. The United 
States Pharmacopeia specifies two types of Biological Reactivity tests (in vitro and in vivo) to 
measure toxicity of extractables and leachables such as plastics and elastomers.27, 28 It may 
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not be necessary to perform robust genotoxic, mutagenic or carcinogenic studies on every 
indentified leachable throughout a stability study as there may already be supporting data 
available. It may be sufficient to assess the safety threshold based on the molecular 
structure, known toxicity or the known toxicity of closely related compounds. There are 
various databases that a toxicologist may reference as part of a data search such as 
TOXNET®, INCHEM® and  ExPub®. 29, 30, 31 
When developing container closure systems for a pharmaceutical product, 
companies will screen various vendors for each component to assess suitability. The final 
selection process will be based upon the analytical and toxicological data.22 - 41 The roles and 
responsibilities of the final product vendor and the packaging component supplier are well 
outlined by Jenke et al. (2007).42 He defines a collaborative strategy between both parties to 
enable a knowledge sharing platform while protecting the confidential information belonging 
to each individual group. Separately, Pan et al. (2008)43 and Castner et al. (2009)44 propose 
strategies for the determination of leachables in liquid drug products which includes LC, GC, 
UV, PDA and MS analytical technologies. Castner et al. (2009) uses Log D partitioning data 
based on the analyte pKa and solution pH as supporting evidence for leachable 
identification.44 Whichever route of analysis that a company ultimately decides upon there 
are decision tree processes that must be followed to justify the use of any packaging 
component and supporting documentation must be sent to the regulatory authorities.11 
Figure 1.2 represents the decision tree process for data submission to regulatory agencies 
to support drug filings. 
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Figure 1.2: Decision Tree for Data Submission for Inhalation, Parenteral and Ophthalmic   
Drug Products, Adapted from Ref 9 
 
1.2 Analysis of Extractables and Leachables 
 Extractables and leachables are impurities which are related to the product and result 
from product contact with components such as processing equipment during manufacturing 
of the bulk product or from the packaging components of the final container closure 
system.19 Extractable and leachable profiles for each drug product must be generated and 
associated toxicological studies performed to assess potential patient impact.25 The actual 
levels of leachables that migrate into the final product are monitored and quantitated during 
stability studies on the drug product over its intended shelf-life.9, 62 The execution of the 
stability studies not only directly monitors leachable levels. There is the possibility of 
secondary interactions between the API and any migrating substance from the packaging 
system, resulting in the formation of adduct components or alternative degradation 
pathways. The impact of these moieties must also be assessed for daily exposure limits. The 
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concentration of leachables present within a drug product are low (approximately 1 ppm) 
relative to the concentration of the raw materials used in the formulation. For this reason, 
methods must be sufficiently sensitive to be able to detect these low level leachables in the 
presence of the API.  
 To reduce the possibility of observing adverse results at the final stage of product 
development, a comprehensive initial screening of packaging components should be 
performed.10 This also follows FDA recommendations for a Quality by Design (QbD) 
approach to product development. A number of analytical techniques may be necessary to 
generate a total extractables profile due to the variety of potential leachables from a 
complete container closure system. Such analytical techniques include, but are not limited 
to, GC-MS, HSGC-MS, LC-MS, ICP-MS, NMR. 
Limited information can be gathered using traditional LC methodology combined with 
UV detection to generate leachable profiles as a screening method whereby known 
leachable standards are used to build a profile. However, these methods do not provide 
structural information and as such are not reliable as characterisation tools for unidentified 
leachables, as retention time and relative retention to an alternative known standard is the 
only data obtained. The use of photodiode array (PDA) detection permits the generation of 
the UV spectrum of an unidentified leachable. This technique gives some additional 
information as to what class of compounds a particular leachable may fall within but 
structural elucidation is not possible. The application of sub 2 micron particle size columns 
and UPLC systems capable of withstanding 16,000 psi, means that screening of 
extractables and leachables could be achieved in a shorter time with greater resolution and 
sensitivity. These methods would typically be used for qualitative work against an authentic 
standard or for quantitative analysis for known leachables. The use of UPLC for quicker 
analysis is exemplified by Novakova et al.. for the testing of four pharmaceutical 
formulations.  Novakova utilised a 1.7 µm particle size column instead of the traditional 5 µm 
or 3 µm columns. The UPLC system allows shortening analysis time up to nine times 
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comparing to the conventional system using 5 µm particle packed analytical columns. In 
comparison with 3 µm particle packed analytical columns analysis should be shortened 
about three times.45  
 1.2.1 Extraction Methods 
 For the initial assessment of container closure systems during drug development or 
investigations into non-conforming commercial product, the extraction methodology of the 
packaging components is vitally important. The design of the extraction study systematically 
and rationally identifies and qualifies potential leachables. The development of an extraction 
profile allows to some extent the identification of individual extractables from a packaging 
component and provides early stage knowledge as to the potential leachables in the final 
product. The controlled extraction studies should utilise vigorous extraction with different 
solvents and extraction techniques, however, the drug product formulation and the 
constituency of the packaging component will ultimately dictate the extraction study design. 
Elastomeric closures (rubber stoppers) are critical components in the packaging of 
parenteral drug products. Stopper components comprise of a multitude of raw materials such 
as elastomers, sealant, accelerators, antioxidants, plasticizers and dyes. Paskiet (1997) 
developed a profile of the extractables from rubber packaging materials used in aerosol 
valves with a range of organic solvents and stress conditions.46  The base rubbers were 
carbon black filled nitrile elastomers and the propellant system was a mixture of 
chlorofluorocarbons. Paskiet executed an initial extraction study to ascertain which solvent 
mimicked the extraction characteristics of the propellant. The analysis was conducted using 
2-proponal, toluene and methylene chloride. The rubber components were refluxed for 1 h in 
each of the solvents and compared to a propellant soaked mixture. 2 – propanol showed the 
best comparison with the propellant soaked extraction. To maximise the extraction 
efficiency, the rubber was further refluxed in 2-propanol for 7 h (4 + 3). The data analysis 
indicated that the extraction was complete after the initial 4 h period. The extraction solvents 
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were analyzed using HPLC and size exclusion chromatography methods and 14 mg and 7 
mg of glycol and oligomers were detected, respectively. Zhang et al. (2004) applied a 
strategic approach for the identification of extractables from rubber closures used in 
semisolid pre-filled drug applicators.47 Some rubber extractables are known to have an 
adverse patient impact and as such it was necessary to screen their selected rubber 
component for potentially harmful extractables. The rubber was exposed to exaggerated 
extraction conditions as a worst case scenario by refluxing with acetonitrile for 8 h. The 
extracted components were separated and collected as fractions for further identification 
work using a semi-preparative Prodigy ODS, 5 µm, 150 mm ×  10 mm HPLC column. The 
mobile phase system consisted of a gradient over 1-20 min from 70-90% acetonitrile. The 
extracted components were identified using HPLC, GC, MS and compared to authentic 
standards as 4-(1,1-dimethyl-propyl)-phenol, sulfur, 2,6-di-tert-butyl-[1,4] benzoquinone, 
furan-2-yl-(5-hydroxymethyl-furan-2-yl)-methanol and 2-bromo-4-(1,1-dimethyl-propyl)-
phenol. The resulting LC-UV chromatogram is presented in Figure 1.18. 
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Figure 1.18: LC-UV chromatogram of extractables from rubber closure used for pre-filled 
semisolid drug applicators. 4-(1,1-dimethyl-propyl)-phenol (1), sulfur (2), 2,6-di-tert-butyl-[1,4] 
benzoquinone (3), furan-2-yl-(5-hydroxymethyl-furan-2-yl)-methanol (4), and 2-bromo-4-(1,1-
dimethyl-propyl)-phenol (5), (47). 
 In 2009, Corredor et al. executed a comprehensive determination of extractables 
from five different brands of stoppers used for injectable products. The stoppers consisted of 
butyl and halobutyl rubbers, coated and uncoated with proprietary films. The stoppers were 
extracted using three different media, 20% w/v sulfobutylether-ß-cyclodextrin, pH 8 
phosphate buffer and 50/50 v/v polyoxyethylated castor oil/dehydrated alcohol. Each 
medium was placed in glass vials and sealed with each of the  rubber stoppers. The vials 
were then stored in the inverted position and stored at 400C/75% RH and 250C/60% RH. The 
samples were analyzed after 3 and 6 months for the elevated temperature samples and at 
12 and 24 months for the lower temperature samples. The media extracts were analysed 
using ICP-MS, IC, HPLC and GC. An accelerated extraction study was performed to yield 
short term data. rubber stoppers were transferred into volumetric flasks and covered with 2-
propanol. The volumetrics were stored at 70oC for 12 hours. The 2-propanol was removed 
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under vacuum and the sample reconstituted in methanol. These extractions were used for 
method development and establishment of a baseline extractables profile. Corredor et al. 
determined 24 different extractables from the various stopper components with a 
quantitation limit as low as 0.03 ppm and as high as 17 ppm. A standardized procedure for 
the testing of extractables from rubber container closure systems was successfully 
developed and it has been shown that the commonly used stopper formulations yield 
relatively low extractable concentrations. The levels observed of the leachable components 
would pose no direct toxicological risk and as such would not yield any further scrutiny from 
regulatory agencies such as the FDA.41 The observed extractables and associated 
concentrations are presented in Table 1.4. 
Table 1.4: Observed Extractables from Five Rubber Stoppers, Taken from Ref 41 
 
 Jenke et al. (2006) developed a similar screening extraction study on eight tubing 
materials potentially encountered in pharmaceutical production facilities. Jenke analysed 6 
silicone and 2 Santoprene based tubing materials post extraction. However, a combination 
of static and dynamic extractions were implemented. Static extractions were executed using 
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water and ethanol. For the first method, lengths of tubing were autoclaved in water at 121oC 
for 1 hour. Alternatively, the tubing was place in glass vials with 100% ethanol and stored at 
55oC for 24 h. The dynamic extractions were performed pumping various extraction solvents 
through a closed loop tubing system using a perstaltic pump with a flow rate to provide one 
complete loop every 20 min with various total extraction times. A breakdown of the dynamic 
extraction cycles is presented in Table 1.5. The extracts were analyzed using TIC/TOC, pH, 
UV, ICP-AES, LC/MS/UV, GC-MS and Headspace GC-MS.48 
Table 1.5: Dynamic Extraction Cycles for Tubing, Taken From Ref 48 
 
Jenke found that in general the levels of extractables were higher in water than in ethanol. 
Five of the materials had relatively high levels of calcium and magnesium. Two of the 
silicone based tubing materials had higher amounts of heavy metals such as Mo, Ti, Zn and 
Fe. The reinforcement wiring in the tubing was identified as a potential source of these 
metals. Of all the materials tested a silicone based tubing had the lowest level of water-
soluble elements, less than 0.01 ppm. In general the level of all dynamic extracted materials 
was very low illustrating acceptable risk for the implementation of the tubings within a 
production environment. 
Plastic containers are widely used in the pharmaceutical industry and plastic 
components are often in direct contact with the final product. Jenke et al. (2005) investigated 
the interaction between a polyolefin container material and several buffers and media used 
in biopharmaceutical applications.49 A total of 9 extraction solvents were analyzed on a very 
low density polyethylene (VLDPE) material. The extraction solvents were: 
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A. 0.06 M ammonium sulfate, 0.022 M 4-morpholinesulfonic acid (MES, 0.0024 M) 
potassium phosphate, pH 5.4 
B. 0.05 M Tromethamine (Tris), 0.15 M sodium chloride, pH 7.2 
C. 2.0 M Tris 
D. 0.02 M Tris-hydrochloride, 0.05 M sodium chloride, pH 8.0 
E. 0.02 M sodium phosphate, 0.15 M sodium chloride, 0.02% Tween-80, pH 5.5 
F. 1% Tween-80 stock solution 
G. 6.0 M guanidine-hydrochloride 
H. 0.15 M sodium chloride, pH 5.4 
I. Binary ethanol/salt buffer mixtures (15, 30 and 45% (v/v) ethanol in 0.15 M sodium 
chloride, pH 5.) 
The various extractions were stored at 15-30oC for 3 months; 40oC for 6 weeks; and storage 
at 40oC for 3 months. The extraction mixtures were then analyzed using various analytical 
techniques such as pH, UV, TOC, GC, LC, MS, ICE. Hexanoic acid extracted in all solutions 
to its total available pool level. The quantity of extracted stearic acid was found to be greatly 
influenced by buffer polarity and pH as a 100 fold difference was observed across polarity 
and pH range. The combination of Tween based buffer at higher pH resulted in the greatest 
extraction of stearic acid. 
 Jenke et al. (2005) further expanded on the investigations into leachables and 
extractables from plastic contact materials into pharmaceutical product. Jenke determined 
material/water equilibrium interaction constants (Eb) for twelve organic model solutes and a 
non-PVC polyolefin plastic material. Plastic container were fashioned from VLDPE material 
and filled with 250 mL of several different solutions containing the following amounts (vol%) 
in ethanol ( in 0.1% phosphoric acid): 0, 15, 30 and 45%. The filled containers were stored 
for 19 days at 40oC. HPLC/UV/MS analysis was executed on the extracted solutions. The 
effect of solvent polarity on Eb was assessed by examining the interaction between the 
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plastic and selected model solutes in various ethanol/water solvents. In general, logEb, could 
be linearly related to the polarity of the mixture.  
 Wang and Schnute (2010) also analyzed potential leachables from various plastic 
containers.50 The leachables examined within the scope of the work were bisphenol A 
(BPA), 4-n-octyphenol (4-n-OP), 4-tert-octylphenol (4-t-OP) and 4-n-nonylphenol (4-n-NP). 
Low-cost bottle (LCB, water bottles, baby-feeding bottles and food containers) and Brand-
name baby-feeding bottles (BNB) were filled with water and exposed to direct sunlight for 2 
days, microwaved for 5 min and then microwaved for another 5 min. Samples were then 
analysed using LC/MS/MS methodology. All bottled water was found to be free from BPA. 
However, 4-t-OP was found in two bottles at approximately 4 and 6 ppb. 
 Degrazio et al. (2009) executed a study to evaluate a new syringe system from an 
extractables perspective for pharmaceuticals and biopharmaceuticals.51 A controlled 
extraction study was performed using water, 2-propanol and hexane on 2 g of the cyclic 
olefin polymer material. he mixtures were refluxed for 4 hours. Separately, syringes prefilled 
with water were stored for 6 months at 40oC/75% RH. Analysis of all solution was performed 
using HPLC/PDA/MS, GC/MS, GC/MS headspace, ICP and IC. An organic acid leachable 
was detected using the IC at levels of 2.2 – 2.9 µg/mL and confirmed by GC/MS and GC/MS 
headspace. 
 Akapo and McCrea (2008) developed a direct liquid immersion solid phase 
microextraction-gas chromatographic (SPME-GC) method for the determination of 11 
potential volatile organic compounds that may leach from pre-printed foil laminate overwrap 
into aqueous pharmaceutical product filled in LDPE vials.51 The target compounds were 
ethanol, acetone, isopropyl alcohol, ethyl acetate, 2-butanone, n-heptane, isopropyl acetate, 
n-propyl acetate, toluene, diacetone alcohol and 1-proxy-2-propanol. The compounds were 
extracted by SPME using a 100 µm polydimethylsiloxane (PDMS) fibre and desorbed inside 
the GC inlet port for analysis. The compounds were extracted by immersing into a 9 mL 
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sample solution placed in a septum capped glass vial fro 30 min at room temperature under 
constant mixing at 100 rpm. Three other extraction fibres were assessed; 75 µm Carboxen, 
85 µm polyacrylate and 65 µm PDMS/DVB. The PDMS fibre yielded the lowest %RSD for all 
analytes. The method was accurate linear and precise exhibiting interlaboratory precision of 
less than 16%. Huang et al. (2012) also developed a SPME-GC/MS/MS analytical method 
for the determination of 2,4,6-tribromoansole (TBA), 2,4,6-tribromophenol (TBP), 2,4,6-
trichloroanisole (TCA) and 2,4,6-trichlorophenol (TCP) in solid dosages as potential 
leachables from wooden pallets which had been treated with fungicides.52 The solid dose 
tablets were transferred to a 125 mL extraction vessel with 100 mL of 0.1% formic acid 
extraction media for 30 minutes under sonication. A Gerstel Twister® PDMS extraction 
device was placed into the aqueous solutions and mixed at 1000 rpm for 90 minutes. The 
recovery values were between 70 and 100% for three different formulations. 
 The extraction technique used for the analysis of container closure systems is varied 
and the selection of an appropriate technique is dependent on a number of factors such as 
the known constituents of the material and in particular polarity and pH, available apparatus, 
compatibility with separation and detection system and time. Rapid analysis may be 
achieved through use of microwave extraction for an immediate estimation of potential 
extractable. However, the high energies incorporated in this technique may lead to 
degradation of the analytes of interest. Aggressive extraction techniques such as microwave 
energy, pH and polarity extremes should be treated as an absolute worst case assessment. 
It is advisable to accompany these studies with comparative studies of the container closure 
system in contact with the actual drug product or formulation under normal storage 
conditions for the duration of the shelf life of the product to ascertain will actually migrate into 
the commercial product. For an initial screening where no information is available on 
packaging components a mix of extraction solvents is appropriate to cover polarity and pH 
ranges. Table 1.6 provides a summary of extraction techniques employed for various 
packaging components including rubber, PVC, glass adhesives and inks. 
41 
 
Table 1.6: Summary of Extraction Techniques 
Year Author Reference Product Type Product Component Extraction Medium Extraction 
Temperature 
Extraction 
Time 
2009 Corredor 41 Injectable Butyl and halobutyl 
rubber stoppers 
pH3 citrate buffer with 20% w/v 
sulfobutylether-ß-cyclodextrin 
40 6 months 
 pH 8 phosphate buffer  40 6 months 
 50/50 v/v polyoxyethylated castor 
oil/dehydrated alcohol 
40 6 months 
 pH3 citrate buffer with 20% w/v 
sulfobutylether-ß-cyclodextrin 
25 24 months 
 pH 8 phosphate buffer  25 24 months 
 50/50 v/v polyoxyethylated castor 
oil/dehydrated alcohol 
25 24 months 
2006 Jenke 53 Manufacturing Equipment Silicone Tubing Water 121 1 hr 
Ethanol 55 24 hr 
Santoprene Water 121 1 hr 
Ethanol 55 24 hr 
2006 Jenke 48 Pharmaceutical Container Plastic component 
VLDPE 
0.1% phosphoric acid 40 19 days 
85/15 v/v 0.1% phosphoric acid/ethanol 40 19 days 
70/30 v/v 0.1% phosphoric acid/ethanol 40 19 days 
55/45 v/v 0.1% phosphoric acid/ethanol 40 19 days 
2009 Wakankar 54 Biopharmaceutical Bioprocess bag Water unknown unknown 
0.1 M phosphoric acid unknown unknown 
0.1 M Sodium Hydroxide unknown unknown 
Isopropyl alcohol unknown unknown 
50% isopropyl alcohol/water unknown unknown 
10% polysorbate 20 unknown unknown 
10% polysorbate 80 unknown unknown 
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Hexane   
2012 USP 10 Container Plastics Container Plastics Water 70 24 hr 
2004 Zhang 47 Injectable Rubber Stopper Acetonitrile Reflux 8 hr 
2008 Sanches-
Silva 
55 Infant Milk Formula Photoinitiator Amoniac and hexane liquid-liquid 
extractions 
N/A N/A 
Dairy Product Photoinitiator Acetonitrile 70 24 hr 
2010 Wang 50 Bottled Water Plastic bottle Water Direct sunlight 2 days 
microwave 5 min 
microwave 5 min 
2005 Jenke 49 Biopharmaceutical Polyolefin Plastic 
Container 
0.06 M ammonium sulfate, 0.022 M 4-
Morpholinesulfonic acid, 0.0024 M 
Potassium phosphate, pH 5.4 
70 3 days 
0.05 M Tromethamine (Tris), 0.15 M 
sodium chloride, pH 7.2 
70 3 days 
2.0 M Tris 70 3 days 
0.02 M Tris-hydrochloride, 0.05 M 
sodium chloride, pH 8.0 
70 3 days 
0.02 M sodium phosphate, 0.15 M 
sodium chloride, 0.02% Tween-80, pH 
5.5 
70 3 days 
1% Tween-80 stock solution 70 3 days 
6.0 M guanidine-hydrochloride 70 3 days 
0.15 M sodium chloride, pH 5.4 70 3 days 
Binary ethanol/salt buffer mixtures (15, 
30 and 45% (v/v) ethanol in 0.15 M 
sodium chloride, pH 5.4 
70 3 days 
2009 Degrazio 51 Injectable Syringe Barrel Water 40 6 months 
Water Reflux 4 hr 
Isopropyl alcohol Reflux 4 hr 
43 
 
Hexane Reflux 4 hr 
2008 Akapo 51 Aqueous based pharmaceuticals LDPE Foil Laminate Solid Phase Micro Extraction using 
polydimethylsiloxane fibres 
Room Temp 30 min 
2007 Dopio-Garcia 56 Food Packaging Polymeric films Dichloromethane with microwave 55 1 min 
1997 Tiller 57 Pharmaceutical Container Adhesive Water 50 3 Days 
2012 Huang 52 Drug Product Packaging cardboard, 
polyethylene, 
polycarbonate, 
wood pallet 
10/90, v/v, Water/ Acetone                                                                                     
PDMS extraction device placed in 
mixture at 1000 rpm  
Sonication          
Room Temp 
30 min
90 min 
1997 Paskiet 46 Pharmaceutical Container Rubber packaging 2-Propanol                                                                  Reflux 1 hr 
Toluene Reflux 1 hr 
methylene chloride Reflux 1 hr 
2011 Constantinos 58 Eye Drop Solutions Packaging Materials Ophthalmic solutions 2 - 8 10 days 
25 20 days 
40 1 -12 
months 
2012 Grilli 59 Containers and closures looking for 
heavy metals 
HDPE bottle                     
Polypoylene cap              
Elastomeric closure             
Glass Vials   
Water                                                                                                                                  
0.1 N HCL                                                                                                                                
0.1 N NaOH                                                                                                                     
1% Hydrogen Peroxide 
70 24 hr
Water                                                                                                                                  
0.1 N HCL                                                                                                                                
0.1 N NaOH                                                                                                                     
1% Hydrogen Peroxide 
121 autoclave 1 hr
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Water                                                                                                                                  
0.1 N HCL                                                                                                                                
0.1 N NaOH                                                                                                                     
1% Hydrogen Peroxide 
Reflux 24 hr
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1.2.2 Separation and Detection 
The separation and detection of extractables and leachables can pose numerous 
challenges to the analytical scientist given the wide range of physical and chemical 
properties and the fact that they are often present in very small concentrations relative to the 
active pharmaceutical ingredient and other formulation components. To try and overcome 
this problem it is often necessary to use multiple analytical techniques to achieve a global 
assessment of extractables and leachables.  
In 2005 the European Food Safety Authority (EFSA) Rapid Alert System uncovered 
traces of the photoinitiator 2-isopropyl thioxanthone (ITX) in baby milk.60 The photoinitiator is 
used as a UV curing process for inks on packaging materials associated with food products. 
This prompted Sanchez-Silva et al. to develop a multi-method for the analysis of 6 
photoinitiators in milk, Irgacure 184, benzophenone, Irgacure 651, Irgacure 907, Quantacure 
ITX, and Quantacure EHA (2-ethylhexyl-4-dimethylaminobenzoate).55  
After extraction, The chromatographic separation was performed on a Kromasil 100 
C18, 5 µm, 150 mm × 4.0 mm column. The gradient elution system consisted of 20% 
acetonitrile solution increasing to 80% acetonitrile over 18 min. Detection of analytes was 
achieved using a PDA detector, see Figure 1.19. Structural confirmation of the authentic 
standards were performed on an LC with TOF MS. A total of 26 various food packaging 
components were analysed and 9 of the test samples were clear from the presence of any of 
the 6 photoinitiators under investigation.  
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Figure 1.19: LC-UV chromatograms of packaging sample with the photoinitiators Irgacure    
184 (1), Benzophenone (2), Irgacure 651 (3), Irgacure 907 (4), Quantacure ITX (5) and 
Quantacure EHA (6), (55). 
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For the MS analysis, the chromatographic separation was performed on a Zorbax Eclipse 
XDB C18, 150 mm × 4.6 mm, 5 µm column with a C18 pre-column. The mobile phase 
consisted of a water and acetonitrile gradient with formic acid at a flow rate of 1.0 mL/min. 
The gradient elution system consisted of 20% acetonitrile solution for the first two min and 
increased to 80% acetonitrile over 18 min. The organic concentration was increased to 
100% at 23 min until 30 min to elute all components from the column. The MS detector was 
operated in positive mode under electron spray ionization (ESI) interface. The source 
temperature was 200oC and the capillary voltage -4,500 V. The nebulizer pressure was 
maintained at 400 kPa and the dry gas flow rate was 11 L/min. The resulting mass spectra 
are presented in Figure 1.20. 
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Figure 1.20 MS of photoinitiators Irgacure 184, Benzophenone, Irgacure 651, Irgacure 907, 
Quantacure ITX and Quantacure EHA,  (55). 
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 Dopico-Garcia et al. (2007) investigated the presence of phosphite and phenolic 
antioxidants in the presence of various food packaging material and assessed their leaching 
effect into water, acetic acid, 10% ethanol solution and olive oil.61 The antioxidants under 
investigation were butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), AO 
2246, AO 425, Ethanox 330, Irganox 1010, Irganox 1076 and Irgafos 168. Analysis was 
performed on a Symmetry C18, 3.5 µm, 150 mm × 3.0 mm column (flow rate of 0.5 mL/min). 
The injection volume was 20 µL and column temperature was maintained at 30oC. A 
water/methanol mobile phase gradient system was employed for elution of the antioxidants. 
The migration test was performed using a film of sample, approximately 1 dm2, with 165 mL 
of distilled water, 3% acetic acid, 10% ethanol and olive oil. For the aqueous stimulants, the 
DL of the antioxidants was reported at approximately 4.5 × 10-3 mg/dm2 with a QL of approx. 
1.5 × 10-2 mg/dm2. The migration level of the studied antioxidants was found to extremely 
low. 
 Kim et al. (2005) also investigated five antioxidants and seven phthalate plasticizers 
in polymeric materials.62 They employed high temperature liquid chromatography (HTLC) to 
improve mass transfer rate and column backpressures to reduce analysis time and improve 
column efficiency. Utilization of diamondbond and zirconia columns was necessary to 
withstand the high temperatures and minimize stationary phase collapse. Each column was 
screened under various isothermal and temperature gradients with different concentrations 
of acetonitrile. Column efficiency was demonstrated to improve at higher temperatures 
incorporating a thermal gradient. A 1% increase in the concentration of acetonitrile was 
shown to be equivalent to approximately 7oC increase in column temperature. The LC-UV 
chromatograms are presented in Figure 1.21 and Figure 1.22. 
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Figure 1.21: Effect of column temperature on the separation of phthalate plastizers, dipropyl 
phathalate (1), dibutyl phthalate (2), butyl benzyl phthalate (3), dicyclohexyl phthalate (4), 
dioctyl phthalate (5), diisononyl phthalate (6) and trioctyl trimellitate (7), (62). 
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Figure 1.22: Effect of column temperature on antioxidants Irganox 245 (8), Irganox 1098 (9), 
Naugard XL-1 (10), Irganox 1081 (11) and Irganox 1035 (12), (62). 
 
  Noguerol-Cal et al. (2007) developed an UPLC method for the separation and 
quantitation of 10 colorants and 6 antioxidants used as polymer additives.63 The 
development process was taken from 2 separate methods which already existed for the 
analysis of dyes and antioxidants. Traditional HPLC methods were adopted into one UPLC 
method which originally resulted in co-elution of peaks. Consequently, Noguerol-Cal 
implemented a Draped-Lin Blocked Cube-Star design of experiments for the UPLC gradient 
program. This involved running the test sample under various gradient conditions at 
previously identified critical points within the gradient parameters. The resolution of the 
critical pairs was measured for each run. From the data, a main effects plot  was generated 
which affords the optimum conditions for each critical point to yield the most efficient 
separation. The optimized conditions for the analysis consisted of UPLC C18 column,        
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1.7 µm particle size, flow rate of 0.5 mL/min, wavelength of 230 nm, column temperature 
30oC and an injection volume of 3 µL. The LC gradient program is illustrated in Table 1.8. 
The use of the statistical tools by Noguerol-Cal et al. resulted in the development of a 
method in the centre of a design space i.e. a small change from the standard operating 
parameters (nominal) does not negatively impact the robustness characteristics of the 
methodology. This can be visually represented using response surface plots and 
optimization plots to determine most efficient nominal operating conditions. Examples 
optimization and response surface plots can be viewed at 
http://www.jmp.com/support/help/Desirability_Profiling_and_Optimization.shtml. However, 
Noguerol-Cal et al. failed to showed the expected long term process capability of the 
analytical separation. This could have been achieved by executing process capability 
analysis to estimate out of 1 million analytical runs, the expected number of assays which 
would yield chromatographic resolution below the acceptable value. In addition, the team 
have limited the analytical separation to UPLC conditions only. A geometric transformation of 
the analytical conditions to HPLC would allow for dual analysis. The geometric 
transformation consists of scaling the standard operating condition between the analytical 
separations taking into account the inherent difference in particle size and pressures 
between UPLC and HPLC. Finally, a two level fractional factorial design would allow for the 
analysis to be completed in a shorter timeframe. This involves testing at a high and low point 
but not testing every parameter, which allows for a fraction of the test conditions. The 
optimized nominal conditions for the UPLC separation are presented in Table 1.8, with the 
corresponding chromatogram presented in Figure 1.23. 
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Table 1.8: Optimized UPLC Gradient Program for the analysis of 10 colourants and 6 
antioxidants, Adapted from Ref 63. 
Time (min) Water (%) Methanol (%) Curve 
0 40 60 Linear 
0.8 30 70 Linear 
0.9 10 90 Linear 
4.0 0 100 Linear 
4.5 0 100 Linear 
5.0 40 60 Convex 
6.0 40 60 Linear 
 
 
Figure 1.23: UPLC separation of 10 colourants and 6 antioxidants used as polymer 
additives, Adapted from Ref 63. 
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There is a responsibility on manufacturers to identify, characterise and toxicologically 
assess major leachable compounds. It is a regulatory expectation that laboratories would 
use GC-MS or LC-MS or a combination of both to qualitatively analyse leachables. Tiller et 
al.. (2006) qualitatively assessed leachables from a custom made proprietary adhesive using 
LC-MS methodology.57 A combination of an Alliance 2690 HPLC system and a Finnigan 
LCQ MS allowed for the structural characterisation of 2 major aromatic compounds as 
shown in Figure 1.24.  
 
Figure 1.24: Mass Spectra of potential leachables from an adhesive, Ref 57. 
[M + H]
+ 
[M + H]
+
 - C2H4O or CO2 = m/z 429 
[M + NH4]
+ 
m/z 429 - C2H4O or CO2 = m/z 385 
55 
 
 
Fichtner et al. (2004) developed an LC-MS method for the identification and quantification of 
extractables of polypropylene and polyethersulfone namely, 4-hydroxybenzoic acid, ethyl 
ester, diethyl phthalate, bis-(-4-chlorophenyl)-sulfone, benzoic acid-p-tolylester, butylated 
hydroxytoluene and 1,3-di-tert-butylbenzene. The extractables were associated with sterile-
grade filtration cartridges.64 Degrazio (2009) also utilized LC-MS technology to identify an 
organic acid leachable in a Crystal Zenith® syringe barrel for biopharmaceutical 
applications.65 Ito et al. (2005) quantitated the leaching of di-(2-ethylhexyl)phthalate (DEHP) 
and mono-(2-ethylhexyl)phthalate (MEHP) from polyvinyl chloride (PVC) tubing using LC-
MS/MS in various drug solutions. The level of DEHP and MEHP ranged from 0.1 – 50 ppm 
and 0.1 – 5 ppm, respectively. The levels were dependent on the levels of drug additives 
such as castor oil.66 Wang (2012) described his UPLC-MS analysis of leachables from 
bottled water, specifically bisphenol A, octylphenols and nonylphenols.67 LODs were 
reported at approx. 0.05 ppb and a correlation co-efficient of greater than 0.995 for each. In 
the bottles under analysis, bisphenol A, octylphenols, and nonylphenols were detected at 
0.4, 7.1 and 0.2 ppb, respectively. Kopperud et al. (2011) used LC-MS applications to 
identify leachables from acrylate polymers used for orthodontic base-plate materials.68 
Jenke (2005) identified extractables associated with polyolefin containers using LC-
MS. The investigation was centred on the effect of several different buffers and media on 
extractables in biopharmaceutical containers.48 The interaction between buffer/media and 
container was permitted for 6 weeks at 40oC and 3 months at 25 or 40oC. LC-MS analysis 
was performed on the extracted solutions. A Phenomenex Prodigy C8 column, 150 mm × 
4.6 mm, 5 µm particle size and a 10 mM ammonium acetate and methanol mobile phase 
gradient was employed for separation of components. The MS settings consisted of API-ES 
(positive ion): gas temp, 325oC; fragmentor, 65; drying gas, 11.0 L/min; nebulizer pressure, 
35 psig; Vcap, 5000V. Specific ions monitored included caprolactam, 114; Extractable A, 
229; Extractable C, 296; Extractable B, 271. API-ES (negative ion): gas temp, 325oC; 
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fragmentor, 65; drying gas, 11.0 L/min; nebulizer pressure, 35 psig; Vcap, 5000V. Specific 
ions monitored included hexanoic acid, 115; Extractable C, 277; stearic acid, 283. The mass 
spectra are presented in Figure 1.25 and Figure 1.26. 
 
Figure 1.25 LC-MS Positive Ion Mode Water Extract of Polyolefin Material taken from Ref 48 
 
Figure 1.26: LC-MS Negative Ion Mode Water Extract of Polyolefin Material taken from Ref 
48.
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Table 1.7 Summary of Separation and Detection Techniques 
Year Author Reference Product Type Product 
Component 
Analytes Technique Separation Mode Detection 
Method 
Quantitation 
Limit 
  
2009 
  
  
  
Corredor 
  
  
  
41 Injectable 
  
  
  
Butyl and 
halobutyl 
rubber 
stoppers 
  
  
  
2-dibutylamine-4, 6-
dithiol-s-triazine 
(DBAT), 4-
pentylphenol, BHT, 
sulfur, Irganox 1010 
HPLC Waters Xterra MS C18 100 × 4.6 
mm, 5 µm                        
Water:Methanol gradient with 
0.05% TFA 
UV: 220 nm 0.1 ppm, 0.3 
ppm, 0.3 
ppm, 0.1 
ppm, 0.3 
ppm 
  
2,4,4-trimetyl-2-
pentene (TMP), 4-
hydroxy-4-metyl-2-
pentanone, acetone, 
hexanes, isopropanol,          
t-butyl alcohol 
HS-GC RTX-624, 30 m × 0.32 mm, 1.8 
µm                       Helium gas: 
Temperature 40 degrees for 3 
min, increase at 20 degree/min 
to 235 degrees 
Flame 
ionization 
Detector 
0.19 ppm, 
15.8 ppm, 
0.4 ppm, 
0.17 ppm, 
0.14 ppm, 
0.15 ppm 
  
Fluoride, Chloride, 
Bromide 
IC Dionex AS 19, 250 × 4 mm                                     
Water:Methanol gradient with 
100 mM sodium hydroxide 
ED-40
Conductivity 
Mode 
1.0 ppm, 2.0 
ppm, 2.0 
ppm 
  
Aluminium, Calcium, 
magnesium, Silicon, 
Titanium, Zinc 
ICP-AES Plasma Power, 1550 watts: 
nebulizer gas flow, 0.75 L/min 
UV: 396.152 
nm Aluminium           
154.065 nm 
Bromine                   
317.933 nm 
Calcium                    
280.270 nm 
Magnesium                       
251.612 nm 
Silicon                            
334.941 nm 
Titanium                          
213.856 nm 
Zinc 
2 ppm for all   
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2006 
  
  
  
Jenke 
  
  
  
53 Manufacturing 
Equipment 
  
  
  
Silicone 
Tubing, 
Santoprene 
Tubing 
  
  
  
Cyclic Oligomers 
[(CH3)2SiO]n where 
n=5 through n=11 
GC-MS J&W DB-5HT, 30 m × 0.25 mm, 
0.1 µm                                                      
Helium gas: Temperature 70 
degrees for 3 min, increase at 10 
degrees/min to 250 degrees 
MS 70eV (+), 
mass range of 
45 - 550 amu 
Unknown   
Di-t-butyl phenol LC/MS/UV Waters Xterra MS C18 100 × 4.6 
mm, 3.5 µm                                    
10 mM Ammonium 
Foramte:Acetonitrile gradient  
UV: 210, 230, 
250 and 280 
nm     MS: API-
ES, positive and 
negative ion, 
mass range 80 - 
800 
UV: 380 ppb                         
MS: Not 
detected 
di-octyl adipate, DEHP,                                   
dibutyl phthalate, 
Irganox degradate 
LC/MS/UV Agilent  Eclipse DB C8, 150 × 4.6 
mm, 5 µm                                                  
10 mM Ammonium 
Foramte:Acetonitrile gradient  
UV: 250 nm                                         
MS: API-ES, 
positive ion, 
single ion 
monitoring                     
371 m/z di-
octyl adipate                   
391 m/z DEHP                                   
279 m/z Dibutyl 
phthalate                 
296 m/z 
Irganox 
degradate 
 UV: 410 ppb,
Not 
Detected, 
350 ppb, 720 
ppb                                           
MS: 10 ppb, 
10 ppb, 20 
ppb, 90 ppb 
  
29 elements ICP-AES Cyclonic, double pass glass spray 
chamber and V-groove nebulizer 
Unknown Lowest: Ca 
0.004 ppm           
Highest: Mg 
1.799 ppm 
  
2006 Jenke 48 Pharmaceutical 
Container 
Plastic 
component 
VLDPE 
Caprolactam, 1,4-
Dioxacyclotetradecane-
5-14-dione (CE1), 3,3-
Dimethyl-1,5-
dioxacycloundecane-
6,11-dione (CE2), 3-
(3,50Di-t-butyl-4-
LC-MS Phenomenex Prodigy C8, 150 × 
4.6 mm, 5 µm                                                  
10 mM Ammonium 
Foramte:Acetonitrile gradient  
MS:                                                    
ES (+) 114 m/z  
Caprolactam            
ES (+) 229 m/z 
CE1                           
ES (+) 271 m/z 
CE2                          
0.01 ppm for 
all except HA 
which is 0.05 
ppm 
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hydroxyphenyl) 
propanoic acid (ID2), 
Hexanoic acid (HA), 
Stearic acid (SA) 
ES (+) 279 m/z 
ID2                           
ES (-) 115 m/z 
HA                           
ES (-) 283 m/z 
SA         
2004 
  
Zhang 
  
47 Injectable 
  
Rubber 
Stopper 
  
4-(1,1-dimethyl-
propyl)-phenol, sulfur, 
2,6-di-tert-butyl-[1,4] 
benzoquinone, furan-
2-yl-(5-hydroxymethyl-
furan-2-yl)-methanol  
and 2-bromo-4-(1,1-
dimethyl-propyl)-
phenol.  
HPLC Phenomenex Prodigy C18, 150 × 
3.2 mm, 3 µm                           
Water:Acetonitrile gradient 
UV: 220 nm Unknown   
4-(1,1-dimethyl-
propyl)-phenol, sulfur, 
2,6-di-tert-butyl-[1,4] 
benzoquinone, furan-
2-yl-(5-hydroxymethyl-
furan-2-yl)-methanol  
and 2-bromo-4-(1,1-
dimethyl-propyl)-
phenol.  
GC-MS Restek Rtx-5, 30 m × 0.25 mm, 
10 µm                                                        
Helium gas: Temeperture 
gradient 100 degrees for 1 min, 
increase at 10 degrees/min to 
250 degrees 
MS 70eV  EI 
ionization                 
MS Methane CI 
ionization 
Unknown   
2008 
  
Sanches-Silva 
  
55 Infant Milk 
Formula 
  
Photoinitiator 
  
Irgacure 184, 
Benzophenone, 
Irgacure 651, Irgacure 
907, Quantacure ITX, 
Quantacure EHA 
  
HPLC Kromasil 100 C18, 150 mm × 4.0 
mm, 5 µm                                          
Water: Acetonitrile gradient 
PDA: Irgacure 
184 - 246 nm 
Benzophenone 
- 256 nm                                 
Irgacure 651 - 
256 nm                      
Irgacure 907 - 
306 nm                    
Quantacure ITX 
- 386 nm                     
Quantacure 
30 µg/L for 
all  
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EHA - 310 nm 
HPLC -MS Zorbax Eclipse XDB C18, 150 mm 
× 4.6 mm, 5 µm                   
Water:Acetonitrile with 0.1% 
Formic acid gradient 
ESI in positive 
mode 
Unknown   
2010 Wang 50 Bottled Water Plastic bottle bisphenol A (BPA), 
4-n-octyphenol (4-n-
OP), 4-tert-
octylphenol (4-t-OP) 
and 4-n-nonylphenol 
(4-n-NP) 
uHPLC/MS/MS Dionex Acclaim PolarAdvantage 
II RSLC column 50 mm × 2.1 mm, 
2.2 µm                                                                 
Water:Methanol gradient 
APCI Negative 
MRM mode. 
Detection 
optimized for 
each analyte 
using 
"compound 
optimization" 
manual 
BPA - 0.12 
ppb                      
4-n-OP - 0.12 
ppb                       
4-t-OP  - 0.13 
ppb                        
4-n-NP - 0.17 
ppb                
  
2005 
  
Jenke 
  
49 Biopharmaceutical 
  
Polyolefin 
Plastic 
Container 
  
Caprolactam, 1,4-
Dioxacyclotetradecane-
5-14-dione (A), 3,3-
Dimethyl-1,5-
dioxacycloundecane-
6,11-dione (B), 3-(3,5-
Di-t-butyl-4-
hydroxyphenyl) 
propanoic acid (C), 
Hexanoic acid (HA), 
Stearic acid (SA) 
IEC Dionex HPICE-AS1                                                                               
Mobile phase 1 mM 
Hydrochloric acid with 5 mM 
tetrabutylammonium hydroxide 
regenerant. 
Unspecified 0.2 ppm for
all 
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Caprolactam, 1,4-
Dioxacyclotetradecane-
5-14-dione (A), 3,3-
Dimethyl-1,5-
dioxacycloundecane-
6,11-dione (B), 3-(3,5-
Di-t-butyl-4-
hydroxyphenyl) 
propanoic acid (C), 
Hexanoic acid (HA), 
Stearic acid (SA) 
HPLC/MS/UV Phenomenex Prodigy C8, 150 × 
4.6 mm, 5 µm                                   
10 mM Ammonium 
Formate:Acetonitrile gradient  
UV: 230                                                
MS:                                                    
ES (+) 114 m/z  
Caprolactam             
ES (+) 229 m/z 
A                         
ES (+) 296 m/z 
C                          
ES (+) 271 m/z 
B                           
ES (-) 115 m/z 
HA                             
ES (-) 277 m/z 
SA                                
0.2 ppm for
all 
  
2009 
  
  
Degrazio 
  
  
65 Injectable 
  
  
Syringe Barrell 
  
  
Screening run - none 
specified 
HPLC/PDA/MS Unspecified Unspecified Unknown   
25 elements ICP-AES Unspecified Unspecified 1.0 ppm for 
all 
  
Fluoride, Chloride, 
Nitrite, Bromide, 
Nitrate, Phosphate, 
Sulfate 
IC Unspecified Unspecified 0.5 - 1.0 ppm   
2008 Akapo 51 Aqueous based 
pharmaceuticals 
LDPE Foil 
Laminate 
Ethanol, acetone, 
ispropyl alcohol, ethyl 
acetate, 2-butanone, n-
heptane, isopropyl 
acetate, n-propyl 
acetate, toluene, 
diactone alcohol, 1-
propoxy-2-propanol, 
isobutyl alcohol 
GC J&W DB-1701, 30 m × 0.53 mm, 
1.5 µm                                                 
Helium gas: Temperature 35 
degrees for 20 min, increase at 
10 degrees/min to 200 degrees 
Flame 
ionization 
Detector 
4.2 ppm, 0.4 
ppm, 1.5 
ppm, 0.05 
ppm, 0.2 
ppm, 0.01 
ppm, 0.02 
ppm, 0.01 
ppm, 0.005 
ppm, 1.2 
ppm, 0.05 
ppm 
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2007 Dopio-Garcia 56 Food Packaging Polymeric 
films 
Butylated 
hydroxyanisole (BHA), 
2,4,bis(tert-
butyl)phenol (DBP), 
2,6-di-tert-butyl-p-
cresol (BHT), 2,2-
methylenebis(4-
methyl-6tert-
butylphenol) (AO2246), 
,2-methylenebis(4-
ethyl-6tert-
butylphenol) (AO425), 
Irganox 1010, Ethanox 
330, Irgafos 168 ox, 
Iganox 1076. 
HPLC Symmetry C18 150 × 3.0 mm, 
3.5 µm                                                        
Water: Methanol gradient 
aqueous samples                                    
Water:Methanol:Acetonitile:THF 
gradient for oil samples 
UV: 276 nm 
Aqueous 
sample                                   
UV: 220 nm Oil 
Sample 
1.4 × 10-2 
mg/dm2             
1.5 × 10-2 
mg/dm2            
1.7 × 10-2 
mg/dm2                     
1.5 × 10-2 
mg/dm2                 
1.4 × 10-2 
mg/dm2                  
1.2 × 10-2 
mg/dm2                               
1.2 × 10-2 
mg/dm2                  
1.6 × 10-2 
mg/dm2              
1.5 × 10-2 
mg/dm2 
  
1997 Tiller 57 Pharmaceutical 
Container 
Adhesive Adhesive screening run 
- none specified 
HPLC- MS Waters Novapak C18 150 × 2.1 
mm                                        
Water:Acetonitrile gradient with 
0.1% acetic acid  
UV:220 nm                                        
MS: APCI 
positive mode                       
MS: ESI 
poisitive  mode 
Unknown   
2012 Huang 52 Drug Product 
Packaging 
cardboard, 
polyethylene, 
polycarbonate, 
wood pallet 
2,4,6-tribromoansole 
(TBA), 2,4,6-
tribromophenol (TBP), 
2,4,6-trichloroanisle 
(TCA) and 2,4,6-
trichlorophenol (TCP) 
GC-MS/MS DB5 ultra inert (5% 
phenylmethyl-siloxane) capillary 
20 m × 0.18 mm, 0.36 µm                                                           
Helium gas: Temperature 65 
degrees for 1 min, increase at 25 
degrees/min to 285 degrees 
Multiple 
reaction 
monitoring 
(MRM):                                             
TBA: 346 - 331 
qunatifier                      
346 - 303 
qualifier                             
TCA: 212 - 197 
quantifier                       
212 - 169 
qualifier                                   
TCP: 196 - 132 
2,500 
ng/tablet for 
halophenols 
and 100
pg/tablet for 
halanisols 
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quantifier                     
196 - 160 
qualifier                                  
TBP: 330 - 222 
quantifier             
330 - 250 
qualifier 
1997 Paskiet 46 Pharmaceutical 
Container 
Rubber 
packaging 
Acenphthylene, 
Phenanthrene, 
Anthracene, 
Fluoranthene, Pyrene 
SEC                       
HPLC 
Unspecified SEC - RI                                                    
HPLC - PDA 
Unspecified  
2011 Constantinos 58 Eye Drop 
Solutions 
Packaging 
Materials 
1,3-Butadiene GC W125-9134 DB-ALCI capillary 30 
m × 0.53 mm, 3.0 µm                                                           
Helium gas: Temperature 85 
degrees for 11 min 
FID 0.5 ppm    
2012 Grilli 59 Containers and 
closures looking 
for heavy metals 
HDPE bottle                     
Polypoylene 
cap              
Elastomeric 
closure             
Glass Vials   
Arsenic, Cadmium, 
Mercury, Lead, Iron, 
Copper, Zinc 
AA                                 
ICP-OES                                
ICP-MS 
Unspecified                                                                                          
Unspecified                                                                                     
Unspecified          
Flame
atomization     
Wavelengths 
unspecified             
m/z unspecified                                      
ppb range   
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1.3 Summary/Concluding remarks  
The strategy taken for the extraction, separation and detection of extractables and 
leachables is very much dependent on the overall goal of the investigation. For the 
qualification of a new packaging material whereby a number of potential candidates have 
been identified and very little information is known about the chemical composition of the 
individual components it would be important to execute a comprehensive extraction study to 
establish an extractable profile of each. The assessment should be performed using solvents 
across the polarity range such as water, 2-propanaol and hexane at defined temperature 
and time periods. A typical extraction study on individual packaging components would be 
for 70oC for 24 hours. The temperature may be lowered but it is recommended to extend the 
extraction time accordingly. If information is required immediately regarding the extractable 
profile and time does not allow for extraction studies to be executed over a number of days, 
a microwave extraction may be used to extract leachables from packaging components in 
minutes. The microwave extraction method may lead to primary and secondary degradation 
of the leachable component due to the microwave energies. Alternatively, if time allows, a 
corresponding leachable study should be executed using the finished product and final 
packaging configuration to determine which potential extractables actually leach into the 
product. Ideally, these studies can be extended out to 6 months at 40oC or to 24 months at 
25oC. 
 Once the extractions have been completed it is important to assess the most 
appropriate analytical technique for separation and identification. If assessing a target 
extractable or leachable which is known and exhibits a chromaphore then simple HPLC-UV 
may suffice to complete the analysis. Alternatively, if the extractable or leachable is unknown 
then tandem LC-MS or GC-MS may be necessary to aid in the structural identification of the 
compounds of interest. MS may also be necessary if the DL or QL is very low, in the region 
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of ppb. These limits may be of critical importance when dealing with components which have 
a high level of toxicological concern. 
The objectives of this thesis is to present a HPLC and UPLC liquid chromatography 
analytical method for the separation of eight potential leachable components and the 
subsequent identification of those compounds by MS. The 8 leachables were specifically 
chosen as they represented constituents of the packaging materials associated with 
ophthalmic formulations. Ophthalmic formulations typically consist of an active ingredient, 
preservative, antioxidants and buffering agents. The ophthalmic formulations are typically 
stored in low density polyethylene containers. The contents of the container are described 
using ink on an adhesive backed label. The bottle is then placed in a cardboard box and an 
adhesive based tamper evident seal is placed over the lip of the carton. The initial separation 
was developed using statistical design of experiment techniques using UPLC technology. 
Upon generation of an analytical methodology centred within a robust design space, the 
operational parameters were geometrically transformed to classical HPLC conditions. The 
dual methodology for the separation allows for the screening analysis to be performed 
irrespective of the LC technology within an analytical laboratory. The leachable analytes 
were identified on an ion trap mass spectrometer using electrospray ionization (ESI) in the 
positive mode. The most common approach to MS detection for liquid samples is 
atmospheric pressure ionization. Of these atmospheric pressure ionization techniques, ESI 
is the most frequently used as it can be used for both high and low molecular weight 
compounds, making it suitable for a great diversity of compounds. The formation of ions in 
ESI is highly dependent on the pKa of the analytes under analysis and the pH of the mobile 
phase. As the mobile phase used is acidified at low pH and typically ophthalmic formulations 
are amine, amide or antibiotic based the positive ion mode was selected for analysis. 
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2. Introduction 
Historically, investment into investigational new drug development eased once the 
therapeutic effect of the active was sufficiently proven through clinical trial studies.1 The final 
challenge was then to bring the product to market. Much of the emphasis has been placed 
upon logistics and marketing campaigns once the product was packaged and ready for sale. 
The container closure system of the final product was chosen for its aesthetic properties and 
overall functionality for the consumer. It was not until recently that the chemical and physical 
properties of the packaging components has come under scrutiny. The potential for analytes 
from the final packaging to migrate into the final product and the impact to the consumer 
must now be assessed.2 A toxicological assessment must be performed on any potential 
leachables and any degradants associated with interactions between the leachables and the 
active pharmaceutical ingredient. It is not only the moral obligation of the pharmaceutical 
companies to show this due diligence but in 1999 The United States FDA issued a guidance 
document in relation to packaging, requirements for new drug products.3 In accordance with 
this guidance document it is the lawful obligation of the pharmaceutical companies to 
establish the compatibility of the drug product with the primary container closure system. 
The challenge of detecting and qualifying potential leachables within formulation 
matrices is often overcome by combining a number of analytical methodologies. Currently, 
chromatographic techniques in tandem with MS analysis are seen as the industry standard 
for the separation of leachables. The volatility (or other physical characteristics) of the 
chemical species will ultimately determine the most appropriate method of analysis. The 
relative low level concentration (ppm) of leachables within pharmaceutical formulations 
requires instrumentation with a significant dynamic range of operation to detect these 
leachable species in the presence of the active pharmaceutical ingredient. The transition is 
being made from LC-UV detection of leachable components to LC-MS technology with the 
increased demand for qualitative analysis of these compounds for toxicological purposes. 
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14,15 Jenke et al. have utilised LC-MS analytical techniques to identify extractables including 
caprolactam, p-toluenesulfonic acid, propionic acid and stearic acid associated with 
polyolefin containers. The interaction between a polyolefin container material and several 
test solution representative of buffers and media used in biopharmaceutical applications was 
investigated under various storage conditions.16 
This work presents a HPLC and UPLC liquid chromatography analytical method for 
the separation of eight potential leachable components and the subsequent identification of 
those compounds by MS. The initial separation was developed using statistical design of 
experiment techniques using UPLC technology and subsequently transformed to HPLC 
conditions. The leachable analytes were identified on an ion trap mass spectrometer using 
electrospray ionization (ESI) in the positive mode.  
2.2 Experimental 
2.2.1 Reagents and Preparation of Standards 
Analytical grade (all purity ≥ 99%) glyceryl triacetate, darocur 1173, toluene, benzophenone, 
diethyl phthalate, methylparaben, 2-phenylphenol and 2,4-ditertbutylphenol were purchased 
under license from Sigma-Aldrich (Poole, UK). The chemical structure of each drug is 
provided in Table 2.1. 
All solvents were HPLC grade or better. Acetonitrile and methanol were obtained 
from Labscan (Dublin, Ireland). Ultrapure water was obtained from a Millipore Milli-Q water 
purification unit (Millipore, Bedford, MA, USA) with specific resistance of 18.2 MΩ/cm or 
better.  Analytical grade formic acid was purchased from BDH Chemicals (Poole, UK). All 
glassware utilised for the storage of leachable stocks and standards were silanised prior to 
the preparation to prevent the leachables from adhering to the glass surfaces. This was 
executed by rinsing the glassware with 10% dichlorodimethylsilane in dichloromethane. This 
was followed by rinsing with dichloromethane and rinsing with methanol twice each. Stock 
solutions of the potential leachables were prepared in methanol to a concentration of 200 
73 
 
ppm and were stored in the refrigerator at 5 oC ± 3 oC. Working solutions were prepared 
freshly before analysis in methanol. The chemical structure and common uses of potential 
leachables are presented in Table 2.1. 
Table 2.1: The Chemical Structure of Potential Leachables 
Analyte Structure Common Use 
Glyceryl Triacetate 
 
 Plasticizer 
 Antifungal agent 
 Gelatinizing 
agent 
Darocur 1173 
 
 Photoinitiator 
Toluene 
 
 Adhesives 
 Paper coating 
 Printing 
 Rubber 
Manufacture 
 Paint 
Manufacture 
Benzophenone 
 
 Photo-initiator 
 UV blocker 
Diethyl phthalate 
 
 Plasticizer 
 Resin solvent 
 Varnish 
 Cosmetic 
Softener 
Methylparaben 
 
 Antifungal Agent 
 Preservative 
2-Phenylphenol 
 
 Fungicide 
 Food additive 
 Disinfectant 
2,4-Ditertbutylphenol 
 
 Antioxidant 
74 
 
2.2.2 Liquid Chromatography 
Initial chromatographic separations were performed on Waters Acquity H-Class UPLC with a 
vacuum degasser, quaternary solvent manager, autosampler and UV detector. Separations 
were performed using a Waters Acquity UPLC BEH C18, 2.1 × 50 mm i.d., 1.7 µm column. A 
multistep gradient was employed with mobile phases of (A) water with 1% (v/v) trifluoroacetic 
acid and (B) methanol with 1% (v/v) trifluoroacetic acid. Gradient conditions were 80% 
mobile phase A with an increase of mobile phase B to 55% over 5 min. The mobile phase B 
concentration was increased to 90% over the next 2 min (total 7 min). The initial gradient 
conditions were reemployed at 7.1 mins at re-equilibrate to a total run time of 11 min. The 
nominal H-Class LC conditions are described in Table 2.2 and the Gradient Program is 
described in Table 2.3. 
Table 2.2:  UPLC Conditions for the Separation of Leachables 
Pump flow rate 0.6 mL/min  
Detector 210 nm 
Column Temp. 45C  
Run time 11 min 
Injection volume 2 µL 
Needle Wash 50% (v/v) Acetonitrile 
UPLC Column Waters BEH C18 
Column Dimensions 50 × 2.1 mm 
Particle Size 1.7 µm 
 
  Table 2.3:  Gradient Program for the Separation of Leachables 
Minutes %A %B Curve No. 
Initial 80 20 * 
5.0 45 55 6 
7.0 10 90 6 
7.1 80 20 6 
11.0 80 20 6 
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2.2.3 Method Optimization  
To ensure method robustness a design of experiments (DOE) was employed to define the 
critical parameters which affect the separation of potential leachables and to optimize each 
of those conditions. The purpose of the DOE was to generate a method which separates the 
components as quick as possible within a robust design space. The critical method 
parameters which affect the separation were defined as: initial concentration of methanol 
(MeOH1), intermediate concentration of methanol (MeOH2), the final concentration of 
methanol (MeOH3), time for the first gradient step (t1), time for the second gradient step (t2). 
 
Figure 2.1: Gradient Profile for Ultra Performance Liquid Chromatography (UPLC) 
A two level fractional factorial DOE was applied to the UPLC process examining the critical 
parameters identified with resolution between the critical pairs in the separation as the 
output. The DOE is outlined in Table 2.4. 
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Table 2.4: Design of Experiment for Separation of Leachables 
Run Order t1 
(mins) 
t2 
(mins) 
MeOH1 
(% B) 
MeOH2 
(% B) 
MeOH3 
(% B) 
1 5 7 20 55 90 
2 7 7 20 55 80 
3 5 9 20 55 80 
4 7 9 20 55 90 
5 5 7 30 55 80 
6 7 7 30 55 90 
7 5 9 30 55 90 
8 7 9 30 55 80 
9 5 7 20 65 80 
10 7 7 20 65 90 
11 5 9 20 65 90 
12 7 9 20 65 80 
13 5 7 30 65 90 
14 7 7 30 65 80 
15 5 9 30 65 80 
16 7 9 30 65 90 
17 6 8 25 60 85 
 
2.2.4 Method Validation 
The precision of the method was obtained by calculating the standard deviation and relative 
standard deviation of the area and peak height data for each leachable. The method was 
assessed via process capability analysis which ensures the method delivers the required 
resolution. The statistical analysis was executed using Minitab® software. 
2.2.5 Geometric Transformation of UPLC Method to HPLC 
The optimized parameters for the UPLC method were geometrically transferred to HPLC 
conditions to allow the method to be run on Acquity (H-Class) and Alliance systems. The 
nominal Acquity (H-Class) conditions are described in Table 2.2. 
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2.2.6 Liquid Chromatography – Mass Spectrometry 
Chromatographic separations were performed on an Agilent 1100 series HPLC with a liquid 
degasser, binary pump, liquid sampler (LS) autosampler, and diode array detector. The LC 
was coupled to a Bruker Daltonics Esquire-LC ESI-ion trap mass spectrometer. Agilent 
Chemstation version A.09.03 (Agilent Technologies, USA) and Bruker Daltonics esquire 
control version 4.0 (Bruker Daltonics, UK) were employed to control the system and data 
analysis was performed using Bruker Data Analysis 2.0 (Bruker Daltonics, UK). Separations 
were performed on a Waters XBridgeTM C18 100 × 4.6 mm, 3.5 µm column. A multistep 
gradient was employed with mobile phases of (A) water with 1% (v/v) formic acid and (B) 
methanol with 1% (v/v) formic acid. Gradient conditions were 77.5% mobile phase A with an 
increase of mobile phase B to 62.5% over 22 min. The mobile phase B concentration was 
increased to 85% over the next 8 min (total 30 min). The initial gradient conditions were re-
employed at 32 min at re-equilibrate to a total run time of 40 min.  
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Table 2.6: ESI-MS Operating Parameters 
Parameter Positive Mode 
Capillary Voltage 4500 
End Plate Offset (V) -500 
Skimmer 1 (V) 40.0 
Cap. Exit Offset (V) 117.3 
Octopole 1 (V) 12.0 
Octopole 2 (V) 1.70 
Octopole RF (Vpp) 162.2 
Lens 1 (V) -5.0 
Lens 2 (V) -60.0 
Trap Drive (Arbitrary units) 37.3 
Dry Gas Flow (N2; L/min) 10.0 
Nebulizer Pressure (psi) 25.0 
Dry Gas Temp. (oC) 340 
Scan (m/z) 50 – 2000 
MS(n) Auto MS(2) 
No. of Precursor Ions 2 
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2.3 Results and Discussion  
2.3.1 LC and Method Optimization 
For the development of the analytical method, 8 model leachable compounds were selected 
to represent the various sources from which extractables and leachables have been known 
to migrate from. Glyceryl triacetate and diethyl phthalate are plasticizers used in the 
manufacture of plastic overwraps or films to bind single units together for distribution to 
market. Darocur 1173 and benzophenone are photoinitiators and are constituents of inks to 
aid in the drying (curing) of ink to paper or plastic substrates. Toluene and 2-phenylphenol 
are used in the manufacture of rubber components and some inks and varnishes. 
Methylparaben is a preservative and antifungal agent used to maintain the integrity of natural 
products such as paper. Finally, 2,4-ditertbutylphenol is an antioxidant used to protect 
packaging components from oxidative degradation.    A gradient LC method was developed 
for the initial separation of the 8 potential leachables on a Waters H-Class system and BEH 
column technology. To assess the performance of the separation, resolution data was 
calculated for each of the components. Resolution was calculated using Empower Software 
and manually calculated using Eqn. 2.1 and the results are shown in Table 2.7 
                                           
               
     
                     (Eqn. 2.1) 
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Figure 2.2:  UPLC chromatogram of a mixture of potential leachables. Peak Identity: (1) 
Triacetin, (2) Darocur 1173, (3) Methylparaben, (4) Diethyl Phthalate, (5) Toluene, (6) 
Benzophenone, (7) Phenyl Phenol, (8) 2,4-Ditertbutylphenol. 
 
Table 2.7: Resolution Data for Eight Potential Leachables 
Leachable tR (min) Rs 
Triacetin / Darocur 1173 1.06 / 1.40 4.95 
Darocur 1173 / Methylparaben 1.40 / 1.92 6.47 
Methylparaben / Diethyl Phthalate 1.92 / 3.82 18.33 
Diethyl Phthalate / Toluene 3.82 / 4.14 2.99 
Toluene / Benzophenone 4.14 / 4.39 2.47 
Benzophenone / Phenyl Phenol 4.39 / 4.87 4.55 
Phenyl Phenol / 2,4-Ditertbutylphenol 4.87 / 7.68 36.77 
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All values were significantly above 1.5 which indicates complete separation of analytes and 
is satisfactory in accordance with the literature.17 This was deemed a good starting point for 
method optimization. The critical pairs in the separation are Diethyl Phthalate / Toluene 
(Peaks 4 & 5) and Toluene / Benzophenone (Peaks 5 & 6) with regard to resolution. A 
critical pair represents the two components of the chromatogram with the lowest calculated 
resolution between them. The resolution between Phenyl Phenol and 2,4-Ditertbutylphenol 
(Peaks 7 & 8) was also deemed critical as an indirect measurement of assay run time. The 
resolution of these critical pairs were monitored during DOE method optimization techniques. 
The resolution results are presented in Table 2.8 
Table 2.8: Design of Experiments and Resolution Results for Critical Pairs 
Run  
Order 
t1 
(mins) 
t2 
(mins) 
MeOH1 
(% B) 
MeOH2 
(% B) 
MeOH3 
(% B) 
Peak (4,5) 
(resolution) 
Peak (5,6) 
(resolution) 
RS (7,8) 
(resolution) 
1 5 7 20 55 90 2.893 2.404 35.514 
2 7 7 20 55 80 2.963 2.392 26.127 
3 5 9 20 55 80 1.928 2.657 32.731 
4 7 9 20 55 90 3.088 2.456 35.676 
5 5 7 30 55 80 5.126 1.987 30.756 
6 7 7 30 55 90 2.25 2.669 33.544 
7 5 9 30 55 90 0 2.924 32.941 
8 7 9 30 55 80 2.195 2.618 35.19 
9 5 7 20 65 80 3.625 2.354 38.68 
10 7 7 20 65 90 1.697 2.688 32.016 
11 5 9 20 65 90 1.231 2.808 31.114 
12 7 9 20 65 80 1.694 2.679 31.568 
13 5 7 30 65 90 3.615 2.315 37.745 
14 7 7 30 65 80 1.079 3.057 36.69 
15 5 9 30 65 80 1.021 3.165 34.966 
16 7 9 30 65 90 1.076 3.102 33.034 
17 6 8 25 60 85 2.22 2.686 42.621 
 
To assess the impact of each vital operational parameter on the resolution of the critical 
pairs, response surface plots were generated. Each critical pair was monitored in isolation 
without consideration for the impact on the remaining two critical pairs. This approach allows 
for direct in-depth analysis on the effect of changing any of the 5 operational factors on the
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resolution of each of the critical pairs.  The response surface plots for resolution between 
diethyl phthalate (DEP) and (TOL) are presented in Fig. 2.3. As T1 increases the resolution 
between DEP and TOL decreases. Maximum resolution is attained if T1 is set to 5 min and 
T2 is set to 7 min. Minimum resolution is attained if T1 is set to 7 min, irrespective of any 
other setting within the design space. As T2 increases, the resolution between DEP and TOL 
decreases. In order to maintain baseline resolution for DEP and TOL, the concentration of 
methanol at point MeOH1 needs to be set as low as possible. An additional increase in the 
concentration of methanol at MeOH2 further reduces the resolution between the critical pair. 
The response surface plots for resolution between TOL and benzophenone (BEN) are 
presented in Fig. 2.4. T1 has minimal impact on the resolution between TOL and BEN. As 
T2 increases resolution increases marginally. However, the concentration of methanol at 
MeOH2 at T2 and the concentration of methanol at MeOH2 relative to MeOH1 has a 
significant impact on the resolution of the critical pair The response surface plots for 
resolution between phenyl phenol and 2,4-ditertbutylphenol are presented in Fig. 2.5. 
Resolution between phenyl phenol and 2,4-ditertbutylphenol should ideally be as low as 
possible as this is an indication of run time. This can be achieved by minimising the 
methanol concentration at MeOH3. It must be noted that this is a secondary consideration as 
resolution between the previously described critical pairs will take precedence over a 
reduction in run time. 
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Figure 2.3:  Response Surface Plots for Resolution between Diethyl Phthalate and Toluene 
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Figure 2.4: Response Surface Plots for Resolution between Toluene and Benzophenone 
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Figure 2.5: Response Surface Plots for Resolution between Phenyl Phenol and 2,4- 
ditertbutylphenol
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While there is merit in evaluating each method parameter in isolation, a true optimization of 
the analytical separation can only be achieved by assessing all variables simultaneously. 
This approach accounts for the singular effects of adjusting any of the critical variables and 
the combination effect of that change with any other variations in the system e.g. a change in 
the initial concentration of methanol may have little impact on separation but if that change is 
combined with a modification to the gradient time, it may have a significant effect. To enable 
a global assessment of all the method parameters and allow for optimization of the analytical 
method an optimization plot was utilized. See Fig. 2.6 for the optimization plot for the 
separation of leachables.  
 Using the data generated from the DOE this tool allows the user to modify each 
method parameter and assess its impact on the separation system. Each point is modified 
so that it operates on a plateau of composite desirability ensuring that the method will 
operate within the centre of a design space while still maintaining optimal resolution between 
the critical pairs. Consequently, small variations in each of the settings which may occur 
from day-to-day, system-to-system or analyst-to-analyst variation will not adversely affect the 
resolution of the critical pairs. The red lines within the optimization plot which define the 
settings can be moved to the left or right (decreased or increased, respectively) and 
resolution is still maintained. The final optimized method parameters for each of the critical 
method variables  as determined from the DOE and optimization plot are presented in Table 
2.9. A comparison of the chromatography pre- and post- optimization is presented in Fig. 
2.7. There is a 10% reduction in the run time of the analysis with acceptable resolution 
maintained for the critical pairs. This reduction in run time is of critical importance to a 
pharmaceutical company whereby real time data is required to support rapid response to 
Ministry of Health‟s or other government regulators. It is never a case that a single sample is 
analyzed within and QC or stability testing environment. Often there are at least 15-20 
samples analysed in the one assay and as such the savings in efficiency can be significant 
when run time is minimised. The 10% reduction in run time in this instance is applicable to 
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both UPLC and HPLC operating conditions. There is further method assurance that the 
operational parameters exist within the centre of a design space. Consequently, the method 
is sufficiently robust to withstand additional external variation which may be associated with 
day-to-day, system-to-system or analyst-to-analyst factors without compromising the 
resolution of components. To support baseline resolution of 1.5 under normal operating 
conditions in different laboratories, it is expected to develop the method with resolution 
between the critical pairs to be no less than 2.0.17 
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Figure 2.6: Optimization Plot for the UPLC Separation of Leachables. 
Table 2.9: UPLC Optimal Gradient Program for the Separation of Eight Leachables 
Minutes %H2O %MeOH Curve No. 
Initial 77.5 22.5 * 
5.50 37.5 62.5 6 
7.50 17.0 83.0 6 
7.60 77.5 22.5 6 
10.0 77.5 22.5 6 
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Figure 2.7: Top: UPLC chromatogram for the separation of 8 leachables before optimization 
Bottom: UPLC chromatogram for the separation of 8 leachables after optimization 
 
The process capability (CpK) refers to a range of Key Performance Indicators (KPIs) that 
measure the ability of the method to deliver the resolution that the analyst requires. Process 
capability is a comparison between the total variation of the process and range of 
acceptability. The Lower Specification Limit (LSL) for the resolution parameters is 1.5 and 
the normal distribution in this case represents the variation of the method with regard to 
resolution. CpK values are used to determine the actual capability of the method using Eqn. 
2.2       
     
    -                   
       
                             (Eqn. 2.2) 
Typically a CpK value above 1.25 is acceptable for a one side specification and a CpK value 
above 2 is considered excellent as the specification window is twice as wide as the process 
variation. The resolution between diethyl phthalate and toluene is normally distributed and 
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centred on an average of 2.54. There is excellent repeatability with a  standard deviation 
(sigma) of 0.011. The CpK value is 30.38 illustrating that short and long term method 
robustness is highly probable. The resolution between toluene and benzophenone is 
normally distributed and centred on an average of 2.83. There is excellent repeatability with 
a  standard deviation of 0.007. The CpK value for the long term resolution of the toluene and 
benzophenone is 57.19. The resolution between these two critical pairs was previously 
identified as a measure of success for the development and optimization of the method. The  
part per million (ppm) total for both critical pairs is 0.0. This means that if the analytical test 
was run 1 x 106 times as described by the analytical procedure the resolution of the critical 
pairs would never fall below the baseline resolution of 1.5. This is critical for a QC laboratory 
whereby timelines and project milestones do not allow for invalid analytical assays due to 
poor resolution of chromatographic peaks. The data indicates that the method is centred in a 
design space of method robustness. 
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Figure 2.8: Process Capability graph for resolution between diethyl phthalate and toluene 
using optimized UPLC method 
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Figure 2.9: Process Capability graph for resolution between toluene and benzophenone 
using optimized UPLC method 
The UPLC method was geometrically transferred to HPLC conditions using a 
Waters® calculator, whereby the method parameters of the UPLC assay were inputted into 
the data system such as column chemistry, length diameter, particle size, flow, and current 
gradient. Following the basic principles of the Van Deemter curve the program calculates the 
relevant length, diameter and particle size, flow and gradient profile under HPLC conditions. 
The geometric transformations can pose some problems especially when working with 
gradient methods as differences in void volumes within HPLC and UPLC methods can pose 
a lot of troubleshooting issues. Many routine stability testing laboratories would still be in the 
process of transitioning from the traditional HPLC systems to alternative technology which 
can operate at much higher pressures i.e. UPLC. The transformation includes changes to 
injection volume, run time, dwell volumes, injection volume, column technology and particle 
size of the packing. 
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Table 2.10:  Optimal UPLC and HPLC Conditions.  
Parameters UPLC Conditions HPLC Conditions 
Pump flow rate 0.6 mL/min  1.4 mL/min  
Detector 210 nm 210 nm 
Column Temp. 45C  45C  
Run time 11 min. 40 min. 
Injection volume 2 µL 20 µL 
Needle Wash 50% (v/v) Acetonitrile 50% (v/v) Acetonitrile 
UPLC Column Waters BEH C18 Waters XBridge C18 
Column Dimensions 50 × 2.1 mm 100 × 4.6 mm 
Particle Size 1.7 µm 3.5 µm 
 
 
 
  Table 2.11:  Optimal Gradient Program for UPLC and HPLC Conditions 
Minutes 
(UPLC) 
Minutes 
(HPLC) 
%A %B Curve No. 
Initial Initial 77.5 22.5 * 
5.50 22.5 37.5 62.5 6 
7.50 30 17.0 83.0 6 
7.60 31 77.5 22.5 6 
10.0 40 77.5 22.5 6 
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Figure 2.10: (a) HPLC chromatogram for leachables. Peak Identity: (1) Triacetin, (2) 
Darocur 1173, (3) Methylparaben, (4) Diethyl Phthalate, (5) Toluene, (6) Benzophenone, (7) 
Phenyl Phenol, (8) 2,4-Ditertbutylphenol. 
b) UPLC chromatogram for leachables. Peak Identity: (1) Triacetin, (2) Darocur 1173, (3) 
Methylparaben, (4) Diethyl Phthalate, (5) Toluene, (6) Benzophenone, (7) Phenyl Phenol, (8) 
2,4-Ditertbutylphenol. 
 
 
2.3.4 LC-MS 
Simple molecular ion spectra were recorded for the leachable components that yielded an 
effective response for the protonated molecular ion [M+H+]. Table 2.12 summarises the 
parent and product ion transitions for each of the  leachable components. 
 
 
 
 
HPLC Run Time 40 mins 
UPLC Run Time 10 mins 
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Table 2.12: Precursor and Product ions recorded for LC-MS of Leachables 
Leachable m/z Precursor Ion m/z Product Ion  
Triacetin 219 [M+H+] 241 [M+H+] + [Na] 
 219 [M+H+] 159 [M+H+] – [C2H4O2] 
 159 [M+H+] – [C2H4O2] 181 [M+H
+] – [C2H4O2] + [Na] 
Methylparaben 153 [M+H+]  122 [M+H+] – [CH3O] 
 153 [M+H+] 154 [M+H+] + [H+] 
Daracur 1173 165 [M+H+] 187 [M+H+]+ [Na] 
 165 [M+H+] 147 [M+H+] – H2O 
 165 [M+H+] 119 [M+H+] – [C2H7O] 
 119 [M+H+] – [C2H70] 91 [M+H
+] – [C2H7O] – [CO] 
Diethyl Phthalate 223 [M+H+] 245 [M+H+] + [Na] 
 223 [M+H+]  177 [M+H+] – [C2H5O] 
 177 [M+H+] – [C2H5O] 149 [M+H
+] – [C2H5O] – [C2H5] 
Benzophenone 183 [M+H+]  206 [M+H+] + [Na] 
 183 [M+H+]  184 [M+H+] + [H] 
 183 [M+H+]  106 [M+H+] - [C6H5] 
2,4-ditertbutylphenol 207 [M+H+]   
Phenylphenol 171 [M+H+]   
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The MS signals for each leachable were generally due to loss of distinct groups from each 
structure. Simultaneously, addition of sodium adducts (23 mass units) to the parent molecule 
are also confirmation of the parent structure, as is the case for triacitin, darocur 1173, diethyl 
phthalate and benzophenone resulting in product ions of 241,187, 223 and 206, 
respectively. The molecular ion of triacetin loses an acetic acid group with a m/z 60, resulting 
in a product ion of m/z 159. This product ion binds with sodium to yield a further product ion 
of 181. The precursor ion of methylparaben loses a methoxide group (m/z 31) to yield a 
product ion of m/z 122. The product ion also exhibits double protonation with a signal at 154. 
Daracur 1173 loses a water moiety (18 mass units) from the parent ion of m/z 165. This 
parent ion also fragments by losing an ethoxonium ion to give a product ion of 119. Further 
subsequent loss of a carbonyl group affords the ion at m/z 91. The diethyl phthalate 
precursor ion (223) loses the ethoxide group into a product ion with m/z 177. This product 
ion further fragments with the loss of an ethyl group to give the new product ion with m/z 
149. Benzophenone also exhibits double protonation and loss of a benzene group (m/z 77) 
to give the product ion at 106 m/z. The leachables with contain benzene rings exhibit π-π 
stacking and result in signals at much higher m/z regions than the molecular ion. This is 
particularly evident in the spectrum for daracur 1173, benzophenone and 2,4-
ditertbutylphenol. The major challenge in the analysis of phenolic compounds is to attain the 
high sensitivity required for determination of these compounds, at ppm level, present in 
many pharmaceutical samples. Compounds with phenolic groups have been determined by 
a variety of methods including gas chromatography/MS (GC/MS) after solid phase extraction 
(SPE) and derivatization by trimethylsilation and HPLC with fluorescence detection.18 
Recently, LC electrospray ionization mass spectrometry (LC-ESI-MS) and tandem MS (LC-
ESI-MS/MS) in the negative ion mode have been employed to analyze these compounds.19 
However, many phenols are not strong acids and therefore show low ionization efficiency in 
ESI-MS. 
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Figure 2.11: (a) UV Chromatogram, (b) Extracted Ion Chromatogram and (c) Mass Spectra 
of Triacetin. 
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Figure 2.12: (a) UV Chromatogram, (b) Extracted Ion Chromatogram and (c) Mass Spectra 
of Methylparaben. 
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Figure 2.13: (a) UV Chromatogram, (b) Extracted Ion Chromatogram and (c) Mass Spectra 
of Daracur 1173. 
 
 
 
 
Figure 2.14: (a) UV Chromatogram, (b) Extracted Ion Chromatogram and (c) Mass Spectra 
of Diethyl phthalate 
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Figure 2.15: (a) UV Chromatogram, (b) Extracted Ion Chromatogram and (c) Mass Spectra 
of Benzophenone 
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Figure 2.16: (a) UV Chromatogram, (b) Extracted Ion Chromatogram and (c) Mass Spectra 
of 2,4-Ditertbutylphenol 
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Conclusion 
An UPLC method was developed for the separation of eight potential leachables from 
container closure systems for pharmaceutical products. The 8 leachables were separated in 
11 min with baseline resolution for all components. The analytical method was further 
optimized using design of experiment (DOE) techniques. The critical parameters which affect 
resolution were identified and assessed using a two level fractional factorial design. 
Response surface plots and optimization plots were employed to optimize each of the 5 
factors. The runtime of the analytical method was subsequently reduced by 9% while 
maintaining resolution between the critical pairs. The method was further validated using 
process capability analysis whereby long term and short term resolution of the critical pairs 
was proven to be sufficient with CpK values of 30.38 and 38.51. The optimized analytical 
method was geometrically transformed to HPLC operating conditions with comparable 
chromatography achieved. The same chromatography profile was achieved with acceptable 
baseline resolution of greater than 1.5. The potential leachables were analyzed using MS 
and structural identification confirmed for 5 of the compounds. However it was not possible 
to structurally identify 3 of the compounds as the phenolic structure meant poor ionization. 
Future work would involve examining a larger number of potential leachables using the 
optimised method. The analytical method should also be assessed for its application to 
detect and resolve leachables from active pharmaceutical ingredients and other final product 
excipients. Further MS work would be executed to ascertain suitable MS methodology for 
the 3 remaining leachables for phenolic compounds. A possible strategy for this analysis 
would be the derivatisation of the phenolic compounds with 1,2-dimethylimidazole-4-sulfonyl 
chloride (DMISC) to improve the ionisability of the compounds. . 
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Chapter 3: Identification of Unknown Leachable in Ophthalmic Solution and Influence 
of Migration Rate 
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3.1 Introduction  
Extractables are defined as compounds which can be extracted from the container/closure 
component during a Stage I testing process.1 Stage I testing may utilize organic solvents, 
elevated temperature or other extraction techniques to aggressively extract compounds for 
materials qualification and investigational purposes. Extractable compounds may or may not 
be present in product stored in the approved container system under International 
Conference on Harmonization (ICH) environmental conditions.2,3,4 Stage I Extractable 
Testing, for a given container/closure component or system, can be considered a one-time 
qualification which may serve as a reference database. Future products, utilizing the same 
container/closure component or system, may then refer to this database and associated 
technical reports to support its qualification for commercial use.  
Leachables are compounds which are detectable in product when stored in the approved 
container system under ICH guidelines. Testing of leachables from product in approved 
container systems is known as Stage II Testing. This stage of testing consists of stability 
studies in the final marketed container closure system. Stage II testing requires that all 
regulatory product shelf-life specifications be monitored with validated analytical procedures 
and be conducted under approved protocols. This stage of testing is also known as a 
Product Compatibility Test. 
 Various analytical technologies have been used to try and identify these 
migrating species from the packaging components such as direct UV and photodiode array 
(PDA).5,6,7 Currently, chromatographic techniques in tandem with mass spectrometry 
analysis are seen as the industry standard for the separation of leachables.8,9,10 The volatility 
(or other physical characteristic) of the chemical species will ultimately determine the most 
appropriate method of analysis.11,12 The relative low level concentration (ppb - low ppm 
range) of leachables within pharmaceutical formulations requires instrumentation with a 
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significant dynamic range of operation to detect these leachable species in the presence of 
the active pharmaceutical ingredient. The transition is being made from LC-UV detection of 
leachable components to LC-MS technology with the increased demand for qualitative 
analysis of these compounds for toxicological purposes. Jenke et al. have utilised LC-MS 
analytical techniques for Stage II testing to identify extractables such as caprolactam, p-
toluenesulfonic acid, propionic acid and stearic acid associated with polyolefin containers at 
a concentration level of 0.2 ppm.7  
Ophthalmic solutions typically consist of a mixture of salts and buffers to control pH 
and a natural polymeric material to serve as a wetting/lubricant agent on the eye. Multidose 
containers utilise a preservative agent within the formulation to maintain product integrity 
over the consumer shelf-life period, approximately 30 days. Alternatively, if the product is for 
single use only, then no preservative is necessary. Finally, if the ophthalmic solution is for 
the treatment of a medical indication, then an API will be incorporated into the formulation 
matrix. These ophthalmic solutions are typically stored in low density polyethylene (LDPE) 
containers. A pre-printed label is placed on the outside of the container using adhesive and 
then stored in a cardboard box with a pre-printed insert. A tamper evident seal is place on 
the carton using adhesive. 12 carton units are bound together using LDPE overwrap film and 
placed in cardboard shippers ready for market distribution. There is potential for leachables 
from plastic, adhesive and inks within this packaging design. This work presents a Stage I 
and Stage II testing study for an ophthalmic solution and associated packaging components 
and the identification of an observed leachable in the final product. 
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3.2 Experimental 
3.2.1 Reagents and preparation of standards and samples 
Analytical grade (all purity ≥ 99%) glyceryl triacetate, darocur 1173, toluene, benzophenone, 
diethyl phthalate, methylparaben, 2-phenylphenol and 2,4-ditertbutylphenol were purchased 
under license from Sigma-Aldrich (Poole, UK). The chemical structure of each drug is 
provided in Table 2.1. 
All solvents were HPLC grade or higher. Acetonitrile and methanol were obtained 
from Labscan (Dublin, Ireland). Ultrapure water was obtained from a Millipore Milli-Q water 
purification unit (Millipore, Bedford, MA, USA) with specific resistance of 18.2 MΩ/cm or 
better.  Analytical grade formic acid was purchased from BDH Chemicals (Poole, UK). All 
glassware utilised for the storage of leachable stocks and standards were silanised prior to 
the preparation to prevent the leachables from adhering to the glass surfaces. This was 
executed by rinsing the glassware with 10% dichlorodimethylsilane in dichloromethane. This 
was followed by rinsing with dichloromethane and rinsing with methanol twice each. Stock 
solutions of the potential leachables were prepared in methanol to a concentration of 200 
ppm and were stored in the refrigerator at 5 oC ± 3 oC. Working solutions were prepared 
fresh before analysis in methanol. 
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3.2.2 Stage I Extraction Study 
Final packaging components for an ophthalmic solution were extracted with appropriate 
solvent mixtures in accordance with USP <661> Plastic Containers.(REF) A list of the 
packaging components is provided in Table 3.1. Each packaging component was placed into 
silanised glass vials with Teflon screw caps containing 20 ml of extraction solvent (50:50, 
methanol:water) and stored at 70oC for 48 h. The samples were vortexed after 24 h. The 
samples were removed from the oven and stored at 5 ± 3oC until time of analysis. A control 
sample consisting of extraction solvent (50:50 methanol:water) was stored under identical 
conditions as the test samples to eliminate any system related or extraction solvent related 
observations.  
Table 3.1: List of Packaging Components for Extraction 
Carton Related Label Related Adhesive Related Ink Related 
Blank Carton Bottle Label Label Adhesive Carton Ink Yellow 
Blank Carton Insert Blank Bottle Label Carton Adhesive Carton Ink Magenta 
Carton Flood-Coat Label Ink  Carton Ink Cyan 
Tape Seal   Carton Ink Black 
Printed Carton   Label Ink 
Carton Insert    
 
3.2.3 Stage II Leachable Study 
A batch of the ophthalmic formulation was manufactured, filled and packaged in its final 
configuration. This test sample was named as “Batch”. A quantity of the same batch of final 
product was filled into glass vials which acted as control samples for final analysis to identify 
leachable artefacts. This glass control sample was named as “Batch-GL”. Simultaneously, a 
quantity of the batch was filled into the low density polyethylene bottles. These bottles were 
unlabelled and no other packaging component was used on the bottles. These served as 
additional controls during analysis. This unlabelled control sample was named as “Batch-
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UL”. The test samples and associated controls were stored at three different conditions and 
tested at various time points. 
 One set of samples and associated controls were placed in a stability chamber set at 
25 ± 2oC and 40 ± 5% relative humidity (RH) and tested at the time points outlined in Table 
3.2.  
Table 3.2: Stage II Testing Schedule at 25oC ± 2oC and 40% ± 5% RH 
 Time Point (months) 
Test Initial 3 6 9 12 18 
HPLC 
Leachable 
X X X X X X 
Test samples Batch, Batch-GL & Batch-UL at each timepoint 
 
A second set of samples and associated controls were placed in a stability chamber set at 
30oC ± 2oC and 25% ± 5% relative humidity (RH) and tested at the time points outlined in 
Table 3.3.  
Table 3.3: Stage II Testing Schedule at 30oC ± 2oC and 25% ± 5% RH 
 Time Point (months) 
Test Initial 3 6 9 12 18 
HPLC 
Leachable 
X X X X X X 
Test samples Batch, Batch-GL & Batch-UL at each timepoint 
 
The final set of samples and associated controls were placed in a stability chamber set at 
40oC ± 2oC and 20% ± 5% relative humidity (RH) and tested at the time points outlined in 
Table 3.4.  
Table 3.4: Stage II Testing Schedule at 40oC ± 2oC and 20% ± 5% RH 
 Time Point (months) 
Test Initial 1 2 3 6 
HPLC 
Leachable 
X X X X X 
Test samples Batch, Batch-GL & Batch-UL at each timepoint 
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3.2.4 Liquid Chromatography 
Chromatographic separations were performed using a Waters Alliance HPLC with a vacuum 
degasser, quaternary solvent manager, autosampler and UV detector. Separations were 
performed using a Waters Sunfire® C18, 100 × 4.6 mm i.d., 3.5 µm column. A multistep 
gradient was employed with mobile phases of (A) water/acetonitrile (90/10, v/v) containing 
0.03% perchloric acid and (B) acetonitrile with 0.03% perchloric acid. Gradient conditions 
were 100% mobile phase A for 5 min with an increase of mobile phase B to 30% over 11 
minutes. There was a hold in the gradient for 10 min with a subsequent increase in the 
mobile phase B concentration to 80% over the next 17 min. A final clean up step was 
employed by increasing the mobile phase B concentration to 100% for 3.9 min hold. The 
initial gradient conditions were reemployed at 47.1 mins at re-equilibrate to a total run time of 
53 min. The nominal Alliance HPLC conditions are described in Table 3.5 and the Gradient 
Program is described in Table 3.6. 
Table 3.5:  HPLC Conditions for Leachable Analysis 
Pump flow rate 1.5 mL/min  
Detector 210 nm 
Column Temp. 30C  
Run time 53 min 
Injection volume 50 µL 
Needle Wash Acetonitrile/Water (90/10, v/v) 
HPLC Column Sunfire C18 
Column Dimensions 100 ×  4.6 mm 
Particle Size 3.5 µm 
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  Table 3.6:  Gradient Program for Leachable Analysis 
Minutes %A %B Curve No. 
Initial 100 0 * 
5.0 100 0 6 
16 70 30 6 
26 70 30 6 
43 20 80 6 
43.1 0 100 6 
47 0 100 6 
47.1 100 0 6 
53 100 0 6 
 
 
Figure 3.1: Gradient profile for HPLC analytical method 
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3.2.4.1 Benzophenone Stock Standard (250 ppm) 
25 mg of benzophenone reference standard was quantitatively transferred into a 100 mL 
volumetric flask. 75 mL of acetonitrile was added to the flask and mixed using a magnetic 
stirrer for 1 h. The stir bar was removed and the volumetric brought to volume with 
acetonitrile. The stir was re-introduced to the solution and mixed for a further 20 min. The 
stock standard was stored under ambient laboratory conditions. 
3.2.4.2 Benzophenone Working Standard (5 ppm) 
Using a Class A pipette, 2 mL of the benzophenone stock standard was transferred into a 
100 mL volumetric flask and brought to volume with a diluent of water/acetonitrile (90/10, 
v/v). The solution was mixed for 20 min using a magnetic stir bar. The working standard 
solution was stored under ambient laboratory conditions. This standard was used a 
bracketing standard to quantitate unknown leachables during the Stage II testing. 
3.2.4.3 Benzophenone Detector Sensitivity Solution (DSS) (0.1 ppm) 
Using a Class A pipette, 2 mL benzophenone working standard was transferred into a 100 
mL volumetric flask and brought to volume with a diluent of water/acetonitrile (90/10, v/v) 
and mixed using a magnetic stir bar for 20 min. The DSS solution was used to confirm that 
the system was capable of quantitating low level leachables in the part per million range.  
3.2.4.4 Blank  
A vial of the water/acetonitrile (90/10, v/v) diluent used to dilute the standard and sample 
solutions was transferred into an amber HPLC vial and analysed simultaneously with the 
standards and samples. This blank was used to identify any system related peaks unrelated 
to the sample. 
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3.2.4.5 Sample Preparation 
Samples were pooled into amber glass jars to protect from light to a total volume of 30 mL. 
The samples were vortexed gently to ensure homogeneity. Using a Class A pipette, 1 mL of 
test sample was transferred to a 10 mL amber volumetric flask and brought to volume with a 
diluent of water/acetonitrile (90/10, v/v). The test solutions were mixed using magnetic stir 
bars for 20 min at ambient laboratory conditions. Each test sample was prepared in 
duplicate. In order for any peaks in a specific final container closure configuration to be 
considered a leachable, it must have been observed in both preparations. This eliminated 
spurious, trace level peaks that were not consistently observed which could be due to trace - 
level glassware contaminates. The associated glass and unlabelled controls were prepared 
in the same manner and were analyzed with the test sample. If a peak at the same retention 
time was observed in the control sample and the final packaged batch, and their differences 
in concentration was greater than 30%, a subtraction procedure was used to quantify 
leachable peaks. If the difference was less than 30% then the peak was not deemed a 
leachable and was final product related.  
3.2.5 Liquid Chromatography – Mass Spectrometry 
Chromatographic separations were performed on an Agilent 1100 series HPLC with a liquid 
degasser, binary pump, ALS autosampler, and diode array detector. The LC was coupled to 
a Bruker Daltonics Esquire-LC ESI-ion trap MS. Agilent Chemstation version A.09.03 
(Agilent Technologies, USA) and Bruker Daltonics esquire control version 4.0 (Bruker 
Daltonics, UK) were employed to control the system and data analysis was performed using 
Bruker Data Analysis 2.0 (Bruker Daltonics, UK). Separations were performed on a Waters 
XBridgeTM C18 100 × 4.6 mm, 3.5 µm column. A multistep gradient was employed with 
mobile phases of (A) water with 1% (v/v) formic acid and (B) methanol with 1% (v/v) formic 
acid. Gradient conditions were 77.5% mobile phase A with an increase of mobile phase B to 
62.5% over 22 minutes. The mobile phase B concentration was increased to 85% over the 
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next 8 min (total 30 min). The initial gradient conditions were reemployed at 32 mins at re-
equilibrate to a total run time of 40 min.  
Table 3.7: ESI-MS Operating Parameters 
Parameter Positive Mode 
Capillary Voltage 4500 
End Plate Offset (V) -500 
Skimmer 1 (V) 40.0 
Cap. Exit Offset (V) 117.3 
Octopole 1 (V) 12.0 
Octopole 2 (V) 1.70 
Octopole RF (Vpp) 162.2 
Lens 1 (V) -5.0 
Lens 2 (V) -60.0 
Trap Drive (Arbitrary units) 37.3 
Dry Gas Flow (N2; L/min) 10.0 
Nebulizer Pressure (psi) 25.0 
Dry Gas Temp. (oC) 340 
Scan (m/z) 50 – 2000 
MS (n) Auto MS(2) 
No. of Precursor Ions 2 
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3.2 Results and Discussion 
3.2 Stage I Extraction 
To investigate the potential extractables which may migrate into the extraction medium, the 
analytical chemistry aspect of the investigation necessarily drives the type of extraction 
testing methodology which is selected. The overall goal of such an investigation is to 
separate and identify unknown extractables which are, most probably, present in low 
concentrations (e.g. low ppm) within the container/closure systems. HPLC, however, may 
detect many compounds relating to the extraction medium. Unfortunately, compounds from 
the extraction medium are present in high concentrations relative to the extractable 
compounds which may migrate into it. The extraction medium, therefore, poses a significant 
potential interference to the detection of ppm concentrations of extractables. To overcome 
this potential obstacle, extraction media must be chosen to minimize their interference with 
the detection of extractables. For these reasons an analytically „clean‟ extraction medium 
must be chosen for the detection of extractables in Stage I testing. Hence a 50:50 
methanol:water analytically clean extraction medium was chosen to mimic the solubility 
characteristics of ophthalmic formulations and not pose an interference to MS studies. 
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Table 3.8: Individual Unidentified Leachables Detected from the Extracted  
                 Packaging Components 
Packaging Component Leachable* Average Peak 
Area (n=2) 
Carton Related 
Blank Carton Not Detected Not Detected 
Blank Carton Insert Not Detected Not Detected 
Carton Flood-Coat Not Detected Not Detected 
Tape Seal IUL (0.93) 3.42 x 106 
Printed Carton IUL (0.93) 2.08 x 106 
Carton Insert IUL (0.93) 5.61x 105 
Label Related 
Bottle Label IUL (0.93) 1.01 x 106 
Blank Label Not Detected Not Detected 
Adhesive Related 
Label Adhesive Not Detected Not Detected 
Carton Adhesive Not Detected Not Detected 
Ink Related 
Carton Ink Yellow Not Detected Not Detected 
Carton Ink Magenta Not Detected Not Detected 
Carton Ink Cyan Not Detected Not Detected 
Carton Ink Black Not Detected Not Detected 
Label Ink Not Detected Not Detected 
* IUL is an Individual Unidentified Leachable with a relative retention time when  
   compared to the benzophenone working standard. 
 
High levels of an Individual Unidentified Leachable (IUL) at relative retention time 0.93 were 
observed from the tape seal. The tape seal is a tamper evident seal which is placed on the 
outside of the final product container to alert the customer if the product has been opened 
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previously. The printed carton also contained the aforementioned IUL(0.93) upon extraction. 
The IUL was not detected in the blank carton or any of the carton inks. IUL(0.93) was 
detected in the carton insert but was not detected in the blank carton insert or associated 
inks. Finally, IUL(0.93) was extracted from the bottle label but was not detected in the blank 
label or associated inks. This indicates that the offending IUL has migrated from the tape 
seal through the outer packaging component of the carton to contaminate the carton, carton 
insert and bottle label. 
 
 
 
Figure 3.2: (a) HPLC overlay of tape seal extraction and benzophenone working 
standard.(b) Photodiode array spectrum of leachable IUL (0.93) extracted from tape seal 
 
(a) 
(b) 
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Figure 3.3: (a) HPLC overlay of carton extraction and benzophenone working standard.  
(b) Photodiode array spectrum of leachable IUL (0.93) extracted from carton 
 
 
 
 
 
 
(a) 
(b) 
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Figure 3.4: (a) HPLC overlay of carton insert extraction and benzophenone working 
standard. 
(b)  Photodiode array spectrum of leachable IUL (0.93) extracted from carton insert 
 
 
 
(a) 
(b) 
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Figure 3.5 
(a) HPLC overlay of bottle label extraction and benzophenone working standard. 
(b) Photodiode array spectrum of leachable IUL (0.93) extracted from bottle label. 
 
 
 
 
 
 
 
 
(b) a
(b) 
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3.3 Stage II  
IUL (0.93) was observed in all ophthalmic solutions stored in the final packaging 
configuration at the storage conditions for the routine, intermediate and accelerated stability 
storage conditions. The chromatographic peak named as IUL (0.93) was not observed in 
either the glass control or unlabelled control samples. Therefore, the resulting peak is a 
consequence of a leachable from the container closure system and is not directly related to 
any of the raw materials or reaction by-products of the ophthalmic solution itself. The HPLC 
profile from the stability studies is consistent with the Stage I extraction profile of the tamper 
evident seal, as it elutes an extractable/leachable peak at a relative retention time of 0.93 
when compared to a benzophenone working standard. The UV spectra of IUL (0.93) from 
the Stage I extraction study and IUL (0.93) from the Stage II leachable study are a direct 
match with λmax = 225.7 nm and a secondary chromaphore at 275.2 nm. This indicates that 
the source of the leachable is a constituent of the tamper evident seal.  
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Figure 3.6: (a) HPLC overlay of final product and associated glass control which had been 
stored at 25oC and 40% RH for 12 months. 
(b) Photodiode array spectrum of leachable IUL (0.93) found in final product formulation 
which had been stored at 25oC and 40% RH for 12 months. 
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The concentration of leachable within the ophthalmic solution increased with time across 
each storage condition and began to plateau at approximately 8 ppm. This indicates that 
maximum intake of the unidentified leachable to the end consumer would potentially be less 
than 10 ppm which is below the guidelines of not more than 10 ppm as stipulated by the US 
FDA. The data for each of the storage conditions was evaluated using linear regression 
analysis to ascertain the effect that the storage condition has on the rate of leaching. See 
Table 3.10 for linear equations. The rate of leaching is determined by the slope of the 
regression line. The slope in all 3 cases is positive indicating an increase in the 
concentration of leachable with time. The routine (25oC/40% RH), intermediate (30oC/75% 
RH) and accelerated conditions (40oC/25% RH) afforded slopes of 0.25, 0.43 and 0.93, 
respectively. The highest slope of 0.93 for the accelerated condition indicates that the rate of 
leaching is dependent upon temperature i.e. as the temperature is increased the migration 
rate of the unidentified leachable increases. Therefore it can be concluded that the 
concentration of IUL (0.93) within the ophthalmic solution is dependent on the storage 
temperature and the length of time the product is exposed to those conditions. This theory is 
further substantiated by the execution of ANOVA (Analysis Of Variance). The statistical 
analysis show that variation in the concentration of the unidentified leachable with the 
formulation is significantly impacted by timepoint and condition i.e. Prob > F is less than 0.05 
for 95% confidence. Approximately, 54% of the concentration of leachable is dependent on 
the age of the product, 20% is dependent on the storage condition and 9% is the dependent 
on the interaction between the two. The final 17% of variation in leachable concentration is 
dependent on with sample variation or variation of the analytical method. Reference Table 
3.12 for partition of variation analysis. 
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Table 3.9: Results for IUL(0.93) in Batches Maintained at Various Storage Conditions 
Sample Condition Timepoint 
(months) 
Replicate A 
(ppm) 
Replicate B 
(ppm) 
Glass 
Control 
(ppm) 
Unlabelled 
Control 
(ppm) 
Batch-25 0 0.00 0.00 0.00 0.00 
3 1.03 1.00 0.00 0.00 
6 2.30 2.67 0.00 0.00 
9 3.50 3.35 0.00 0.00 
12 2.79 5.74 0.00 0.00 
18 4.20 4.51 0.00 0.00 
24 6.12 5.34 0.00 0.00 
Batch-30 0 0.00 0.00 0.00 0.00 
3 4.81 3.03 0.00 0.00 
6 5.24 4.75 0.00 0.00 
9 7.43 7.27 0.00 0.00 
12 7.80 7.78 0.00 0.00 
18 7.92 8.63 0.00 0.00 
24 7.66 8.14 0.00 0.00 
Batch-40 0 0.00 0.00 0.00 0.00 
1 3.21 3.25 0.00 0.00 
2 4.18 4.50 0.00 0.00 
3 4.99 5.08 0.00 0.00 
6 6.79 6.01 0.00 0.00 
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Figure 3.7: Trend Graphs for leaching rate of IUL(0.93) at three different storage conditions  
 
Bivariate Fit of Result (ppm) By Timepoint  
 
 
Figure 3.8: Bivariate fit of results (ppm) by timepoint grouped by storage condition. 
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Table 3.10 Linear Fit Equations for the Leaching Rate of IUL  into Ophthalmic Product 
Condition Linear Fit Equation 
25/40 Result (ppm) = 0.5340714 + 0.2570952*Timepoint 
30/25 Result (ppm) = 1.8961429 + 0.4365238*Timepoint 
40/25 Result (ppm) = 1.5591509 + 0.9341038*Timepoint 
 
 
Table 3.11 Summary of Linear Regression Fit for Diethyl Phthalate Leaching 
 Parameter 25/40 30/25 40/25 
Square 0.768 0.795 0.786 
RSquare Adj 0.745 0.775 0.759 
Root Mean Square Error 0.913 1.432 1.120 
Mean of Response 2.590 5.388 3.801 
Observations (or Sum Wgts) 12 12 10 
 
 
 
 
 
 
 
 
 
 
Figure 3.9: Graphical representation of standard deviation by (a) condition and (b) timepoint 
and concentration of the unidentified leachable (ppm) by (c) condition and (d) timepoint. 
 
 
 
 
(a) (b) 
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Table 3.12 Partition of Variation (POV) Crossed, Independent Analysis 
 
Component Pop Variance % of Total Sqrt(Var Comp) F Ratio Prob>F Sig. 
 . . . . .   
Between Total 5.647 83.14 2.376 27.6210 0.0000 * 
  Between Condition 1.388 20.44 1.178 16.9783 0.0000 * 
  Between Timepoint 3.650 53.74 1.911 89.2714 0.0000 * 
  Between Condition*Timepoint 0.608 8.96 0.780 7.4386 0.0026 * 
 . . .    
Within Total 1.145 16.86 1.070    
  Within Condition 0.138 2.03 0.371    
  Within Timepoint 0.076 1.12 0.276    
  Within Condition*Timepoint 0.139 2.04 0.373    
  Common 0.000 0.00 0.000    
 . . .    
Total 6.792 100.00 2.606    
      
 
Figure 3.10: Graphical representation of percent of total variation  
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3.4 MS Analysis 
The tape seal on the outer packaging of the final product uses an adhesives which has high 
concentrations of diethyl phthalate. It was hypothesised that the leaching IUL (0.93) was 
indeed diethyl phthalate. Simple molecular ion spectra were recorded for the diethyl 
phthalate standard, extracted tape seal and the final product which contained the 
unidentified leachable component at relative retention time (0.93). Table 3.11 summarises 
the parent and product ion transitions for the leachable components. 
Table 3.11: Precursor and product ions recorded for LC-MS of diethyl phthalate 
standard and IUL (0.93) from tape seal extraction and IUL (0.93) form ophthalmic 
product 
Leachable m/z Precursor Ion m/z Product Ion  
Diethyl Phthalate 223 [M+H+] 245 [M+H+] + [Na] 
 223 [M+H+]  177 [M+H+] – [C2H5O] 
 177 [M+H+] – [C2H5O] 149 [M+H
+] – [C2H5O] – [C2H5] 
IUL (0.93) from 
Extraction of Tape 
Seal 
223 [M+H+] 245 [M+H+] + [Na] 
 223 [M+H+]  177 [M+H+] – [C2H5O] 
 177 [M+H+] – [C2H5O] 149 [M+H
+] – [C2H5O] – [C2H5] 
IUL (0.93) from 
Ophthalmic Product 
223 [M+H+] 245 [M+H+] + [Na] 
 223 [M+H+]  177 [M+H+] – [C2H5O] 
 177 [M+H+] – [C2H5O] 149 [M+H
+] – [C2H5O] – [C2H5] 
 
The MS signals for each leachable were generally due to loss of distinct groups from each 
structure. The diethyl phthalate precursor ion (223) loses the ethoxide group into a product 
ion with m/z 177. This product ion further fragments with the loss of an ethyl group to give 
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the new product ion with m/z 149. The addition of sodium adducts (23 mass units) to the 
parent molecule are also confirmation of the parent structure i.e. 245 mass units.  
 
 
 
Figure 3.11 UV Chromatogram, Extracted Ion Chromatogram and Mass Spectra of Diethyl 
phthalate 
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Figure 3.12: UV Chromatogram, Extracted Ion Chromatogram and Mass Spectra of 
Extraction of Tape Seal. 
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Figure 3.13: UV Chromatogram, Extracted Ion Chromatogram and Mass Spectra of Final 
product. 
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Conclusion 
A Stage I extraction study was executed on final packaging components for an ophthalmic 
solution with appropriate solvent to ascertain an extractables profile for the various 
components. An extractable at relative retention time 0.93 when compared to a 
benzophenone standard was observed in the tape seal, printed carton, carton insert and 
bottle label. The extractable was shown to have migrated from the tape seal through the 
outer packaging of the product to contaminate the carton, carton insert and bottle label. A 
Stage II study was performed to determine if the extractable leaches into the final product 
and if so, determine what conditions affect the rate of leaching. A corresponding leachable at 
relative retention time 0.93 when compared to a benzophenone working standard was 
observed in the final product under routine, intermediate and accelerated conditions. The UV 
spectra and HPLC profiles indicate that the leachable is a consequence of an analyte 
migration from the tape seal into the final product. Migration rates were analysed using linear 
regression and ANOVA analysis. The rate of migration is dependent primarily on time and 
storage conditions. As time and temperature increases the migration rate of the leachable 
increases. The maximum observed concentration of the leachable was approximately 8 ppm 
which is below the allowed limits of less than 10 ppm as directed by the US FDA. HPLC-MS 
analysis was performed to identify the leachable component. The leachable was 
successfully identified as diethyl phthalate which is a plasticizer used in the manufacture of 
the tape seal. Future work in this area would include selection of 3 alternative tamper evident 
seals to be used on the ophthalmic solution. Alternate plastic based models and paper 
based models would be selected. Further Stage I extraction studies would be executed to 
determine the presence of diethyl phthalate or other volatile phthalate plasticizers. The affect 
of diethyl phthalate has on the active pharmaceutical ingredient (API) within the formulation 
should also be investigated to ascertain if the degradation pathway of the API is altered due 
to the presence of the leachable. 
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Chapter 4: Final Conclusion 
 A screening LC method with UV and MS detection methodologies has been 
developed for 8 potential leachables from packaging components associated with the 
container closure system of ophthalmic formulations. The method was developed using 
statistical techniques such as fractional factorial DOE and process capability analysis. The 
test methodologies are geometrically transferable from HPLC to UPLC instrumentation. 
  A stage I extraction study was executed on the packaging components of an 
ophthalmic product to ascertain potential leachables which were observed in final product. 
Extracts of the tape seal identified the offending leachable as diethyl phthalate and this was 
confirmed via MS analysis.  
 A stage II leachable study was performed at various temperature and humidity 
conditions to determine the stability profile of the product over a significant period of time. 
The rate of leaching was determined to be dependent on temperature. 
 Future work in this area would focus on screening a larger number of potential 
leachables on the newly developed screening method and subsequent derivatization 
techniques to improve sensitivity of phenolic compounds for ESI analysis. Possible future 
work would also focus on screening alternate adhesives to be used on the tamper evident 
seal and assess leaching rates of constituents under the stability storage conditions. 
 
 
